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Chapter I 
Introduction
A. Project Overview
Transcription, in which information stored in the coding regions of the cells 
DNA is converted into RNA is a fundamental cellular process.1 As such, it is highly 
regulated in healthy cells. Aberrant transcription is a hallmark of cancer,2,3,4 and is also 
associated with a host of other pathologies such as metabolic,5,6 inflammatory7,8 and 
neurological disorders.9,10 The proteins responsible for recruiting the transcriptional 
machinery to the promoter, transcriptional activator proteins, contact their target 
proteins, coactivators, through transcriptional activation domains that are often 
relatively short contiguous groups of amino acids.11,12 Because of the central role that 
transcription plays in regulating cell function and fate, the ability to cause a targeted 
increase or decrease in particular transcription programs has tremendous potential as 
both a therapeutic approach, and as a tool for biochemical investigations. 
The design or discovery of ligands, particularly small molecule ligands, that 
target transcription has proven difficult and only a handful of such molecules are 
known.12,13 Prominant obstacles include the promiscuous binding profile of many 
transcriptional activation domains, the low to moderate affinities of activator-
coactivator interactions, and the lack of structural data, or even the identity of, the 
biologically relevent coactivators in most circumstances. High throughput screening 
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against the well characterized coactivators CBP and p300,14,15 or against particular 
phenotypes, such as the death of cells which depend on overexpression of a  particular 
gene,16 have seen isolated successes. However, at the time this work was initiated, a 
general design rationale for small molecule transcriptional inhibitors had not emerged. 
The project described in this dissertation grew out of the hypothesis that small 
molecules which mimic activation domains can be used as scaffolds for the 
development of transcriptional inhibitors. In this work, I will discuss the potential of 
small molecules that mimic the activation domain of the transcriptional activator ESX 
to inhibit the transcription of erbB2, an oncogene whose expression is mediated by 
ESX.17,18,19 This will be followed by the description of a generalizable strategy for 
overcoming some of the limitations of small molecule transcriptional inhibitors. 
The final portion of this thesis concerns the important issue of education in 
research practices. A growing body of work and suggests the widespread use of 
questionable practices by research scientists.20,21, This is supported by the accounts of 
outright fraud and sabotage involving graduate students and post-doctoral researchers 
have appeared in the scientific press.22,23,24 Data from the National Research Council, 
and interviews with those involved indicates that these incidents are connected to 
percieved pressure on those involved. As part of a collaboration with another graduate 
student – Dr. Amy Danowitz – I designed, wrote, and lead a discussion module for 
incoming graduate students about research ethics, data interpretation, and conflict 
management.   
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B. Introduction to Transcription
Transcription is the process by which the information stored in the protein-
coding regions of a cell's chromosomal DNA is converted to RNA, in case of proteing 
coding genes, messenger RNA (mRNA).1 The information contained in the sequence 
of this mRNA is then used by the ribosome to synthesize protein with a particular 
sequence of amino acids. As protein synthesis is one of the principle ways in which 
cells regulate their internal processes, transcription plays a fundamental role in 
determining cell function and fate.2,3 
The actual process of transcription involves the carefully orchestrated 
recruitment of a series of proteins and protein complexes to the target gene. Early in 
this process, transcriptional activator proteins localize to the DNA, usually in the 
promoter region just upstream of their target gene. These transcriptional activator 
proteins then recruit the other proteins or protein complexes required to initiate 
transcription.1 The details of this process, however, are unclear. The direct targets of 
activators and the order and manner in which they are recruited  remains an area of 
active investigation and debate.12 
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The prevaling model suggests that activators must recruit multiple proteins or 
protein complexes in order to facilitate both promoter accessibility and formation of 
the pre-initation complex (PIC) that includes RNA Polymerase II (RNA Pol II), which 
carries out mRNA synthesis.25,26 The first of these function is needed because most 
chromosomal DNA is stored as chromatin, DNA wound up around protein complexes 
called histones that  render the DNA more compact and less accessible.27 Protein 
complexes such as Swi/Snf and SAGA act to alter chromatin structure and location, 
making the target gene more accessible.28,29 A second class of coactivators act as 
scaffolds that link transcription activators and the transcriptional machinery. This 
includes members of the mediator complex,30,31 which is known in many cases to act 
as a bridge between DNA bound activator proteins and RNA Polymerase II. There 
appear to be some unifying features, such as the fact that recruitment of mediator is 
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Figure I-1. Initiation of transcription by transcriptional activator proteins. The 
activator protein binds to a recognition site and recruits proteins or protein complexes 
that alter the chromatin structure to allow access to the target gene. The activator than 
recruits coactivators that in turn recruit RNA Pol II and the rest of the transcriptional 
machinery needed to for the Pre-Initation Complex (PIC) which can begin 
transcription.   
generally required for the activation of transcription. However most of the details, 
such as the particular protein-protein contacts made or even the order of recruitment, 
are unknown for most transcriptional activators. 
C. Structure and Function of Transcriptional Activators and Coactivators. 
C.1. Transcriptional Activator Proteins
Transcriptional activators are modular proteins, minimally comprised of a 
DNA binding domain (DBD), which is responsible for localizing the activator to its 
cognate sequence in the promotor of its target gene(s), and one or more transcriptional 
activation domains (TADs) which are responsible for making contacts with other 
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Figure I-2. Possible interacting partners of transcriptional activator proteins. In most 
cases, the biologically relevant binding partners of a particular activator are disputed 
or unknown. The current model suggests that activators must make contact with 
multiple proteins or protein complexes, likely incuding the three complexes shown 
here: Swi/Snf and SAGA are largely responsible for modifying histones or shifting 
their position in order to facilitate access to the promotor of the target gene, Mediator 
is responsible for recruiting and stabilizing RNA Pol II and the rest of the 
transcriptional machinery.   
members of the transcriptional machinery in order to initiate transcription.1 The 
surprising degree of modularity found in transcriptional activators has been 
demonstrated in experiments where the activation domain of one transcriptional 
activator protein and the DNA binding domain of a different protein were shown to 
effectively initiate transcription.1
In contrast to DNA binding domains, which often have well defined and 
crystalizable structures, transcriptional activation domains are generally poorly 
structured in solution and computational analyses indicate that they have a very high 
incidence of 'intrinsically disordered regions.32 The largest class of activation domains 
– usually called 'acidic' or 'amphipathic' activation domains because of their 
interspersed arrangement of acidic and hydrophobic amino acids – are generally 
thought to form α-helices upon interaction with their coactivator targets.12,33,34,35 In this 
model, the arrangement of amino acids in the TAD allows this domain to form a helix 
with a largely non-polar face for interacting with recognition surfaces on its target 
interaction partners, and a polar face that can remain solvent exposed. An example of 
this is the interaction between the activation domain of vp16 and the general 
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Figure I-3. Anatomy of a transcriptional activator. Activators are minimally 
composed of the two domains shown above. 
transcription factor TFIIH (figure I-4).36 
Although the current model generally assumes a helix, and experimental 
results indicate at least some helical propensity for many activation domains, 
including vp16,36,37 ESX,38 p65,39 and MLL and myb,40 the degree to which most 
activators domains form perfectly canonical helices is unknown. It has been shown 
that individual activation domains are capable of interacting with multiple, non-
homologous co-activators,41,42 indicating that lock and key type rationales are an 
inadequate way to conceptualize activator-coactivator interactions. It has been 
proposed that the relatively unstructured nature of these domains in solution may play 
an important role in their function by allowing them to sample a wide range of 
7
Figure I-4.  Ribbon diagram of the VP16 activation domain. This activation domain 
(red, residues 412-490) is shown interacting with the tfb1 subunit of general 
transcription factor TFIIH (blue), resolved using NMR spectroscopy. PDB ID: 2k2u
conformations and to facilitate interaction with the different proteins needed to initiate 
transcription.32 For example, the potent activator VP16, which is often used in yeast as 
a model for activation in eukaryotes, has been seen to interact with or recruit a variety 
of proteins, including p300 and TFIID,41 mediator subunit 15,43 mediator subunit 25,37 
TFIIH,36 and a combination fo TBP, TFIIB and the SAGA complex.42  
In addition having promiscuous binding profiles, it has also been shown that 
many activator-coactivator interactions have affinities ranging from mid nanomolar to 
low micromolar. For example, a study of the affinities of the activation domains of the 
yeast activators Gal4 and Gcn4, as well as the human activator p53, and the viral 
activators HIV-TAT and VP16 for a variety of transcriptional coactivators found that 
none had binding affinities tighter than 100nM.44 This is supported by a more recent 
analysis of the yeast activators Gcn4 and Gal4, and the viral activator VP16 found that 
even when bound to DNA, their dissociation constants for the coactivator mediator 
subunit 15 (Med 15) ranged from 100-320 nM.43 The overall picture suggested by 
these facts is one in which activators form transient, moderate affinity interactions 
with a series of coactivators in order to recruit the necessary transcriptional 
machinery.  
Although the DNA binding and transcriptional activation modules are the 
minimal requirements for a transcriptional activator, other structural features can be 
present. These often include regulatory elements reponsible for mediating activity and 
interaction with regulatory proteins or dimerization partners. For example, NFκβ 
subunit p65 contains a Rel-homology domain that, in addition to acting as a DNA 
binding domain, mediates contacts with Iκβα – an regulatory factor that inactives the 
DNA binding and nuclear localization functions of the RHD and holds p65 in the 
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cytosol in an inactive state until signals are received for its release.45 The RHD also 
serves as a dimerization domain, allowing p65 to dimerize with p50 in order to 
effectively bind its consensus sequence in the promoter of its target genes.46 
Dimerization in conjunction with DNA binding is a common regulatory motif in 
transcriptional activation, which provides an additional level of control for the cell to 
selectively active particular genes controlled by a given activator. 
C.2. Transcriptional Co-activator Proteins  
 
Two well defined coactivators are the paralogs CBP and p300, which have 
largely overlapping functions within the cell.47 Both CBP and p300 have multiple 
activator binding domains, each of which is known in turn to interact with as many as 
20 different activators.48 These two coactivators likely serve several roles in 
transcriptional activation. Because CBP/p300 are known to bind such a large number 
of transcriptional activators, and are also known to interact with general transcription 
factors such as TFIIB, it is thought the CBP/p300 may act as a bridge between 
targeted transcriptional activators and general elements of the transcriptional 
machinery.49 Additionally, CBP/p300 are known to possess both intrinsic histone 
hcetyltransferase (HAT) activity.50 This activity appears to be important for 
transcriptional activation, as ablation of HAT activity using small molecule 
inhibitors51 or depletion of the cofactor CoA reduces the activation in systems which 
rely on CBP/p300 as a coactivator.41 Finally, CBP/p300 also appear to be able to 
acetylate certain activators or even themselves, thereby regulating the timing and 
order of coactivator recruitment.41,52 
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An essential component of the transcriptional machinery that is contacted 
directly by transcriptional activators is the mediator complex. Mediator is unique to 
eukaryotes, and is largely conserved between yeast and mammals.30 Although the 
structure and composition of the mediator complex appears to depend at least partially 
on promoter context, the complex is generally held to include 26 subunit proteins, 
with a total size of approximately 1.2 MDa.30  Although a complete picture of the role 
of the mediator complex during transcription remains elusive, it is thought that the 
complex acts as a scaffold that, once recruited by transcriptional activator proteins, 
serves to mediate the recruitment and removal of the cofactors necessary for mRNA 
synthesis and termination of the finished mRNA transcript.25,30,53 Mediator is 
instrumental in both the recruitment and the stabilization of RNA Pol II and its 
associated proteins at the promoter.31,53These functions are mediated by extensive 
contacts between RNA Pol II and the 'head' and 'middle' regions of the mediator 
complex.30 The tail region of mediator is the least conserved between yeast and 
mammals. Although this region is dispensable for basal transcription, its loss renders 
genes unresponsive to transcriptional activator proteins indicating that the tail region 
is responsible for making the contacts that allow mediator to be recruited by activator 
proteins.30 
D. Small Molecules and Peptidomimetics that Target Transcription 
D.1. Potential Utility of Agents that Target Transcription 
Given the importance of transcription as a cellular process, the association 
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between mis-regulated transcription and the development of diseased states in 
unsurprising. Cancer is commonly linked to the over-expression of one or more 
proteins that promote uncontrolled cell growth.3,4 One such example is the trans-
membrane tyrosine kinase erbB2, the over-expression of which is responsible for a 
particularly aggressive type of breast cancer.54 In another, the transcription factor HIF-
1α is responsible for mobilizing the cellular response to hypoxia, is over-expressed in 
many cancers, including those of the brain, mammary tissue and reproductive organs, 
where it is associated with increased patient mortality.55 In addition to specific 
examples such as these, there is the general characterization of cancer as a disease of 
mis-regulated gene expression, in which healthy patterns of expression are disrupted, 
leading to core oncogenic attributes such as uncontrolled proliferation,56,18 and 
repression of apoptosis.57,7 Thus, interventions that target transcriptional processes 
could prove to be potent therapeutic tools for treating cancer. In principle, the ability 
to selectively up- or down-regulate particular genes or sets of genes could be used to 
activate tumor suppressive programs, or to reverse oncogenic phenotypes. 
D.2 Challenges in the Development of Agents that Target Transcription
In spite of the potential usefulness of biomolecules or synthetic agents that 
target transcription, the obstacles to the development of a general and effective 
strategy for the exogenous control of transcription are formidable. On the one hand 
protein and (to a lesser extent peptide) based interventions offer the potential for a 
high degree of affinity and selectivity, but the obstacles to delivery include cell uptake 
and subcellular localization, and dosing issues such as oral availability.58,59 On the 
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other hand, although the therapeutic use of small molecules to affect intracellular 
processes is well established, the design of small molecules that target transcription is 
a challenge in itself. The surfaces of protein-protein interactions are generally much 
larger than the surface area of most small molecules.60,61 This may be especially 
problematic in cases such as transcription, where many of the interacting surfaces are 
relatively unstructured, rather than well-defined structures that fit into deep binding 
clefts. Furthermore, other than CBP/p300, little definitive information is available 
about the structures of most coactivators, which are largely composed of intrinsically 
disordered regions.32 In many cases, the relevant coactivator targets of a given 
transcriptional activator are not known, and in cases like CBP/p300 where particular 
domains are targeted by many different activators, it raises serious questions about 
even the theoretical possibility for activator-specific inhibitors. For example, the CH1 
domain of CBP is known to interact with at least 11 different activation domains, 
including NF-κβ subunit p65, the metabolic regulator HNF-4, the tumor suppressor 
p53, the epithelial specific growth inducing transcription factor ets-1, and HIF-1α, 
which mobilizes the cell's response to hypoxia and promotes the growth and 
vascularization of tumors.48,62 It is therefore likely that an inhibitor that binds to the 
CH1 domain will inhibit the ability of any of these transcriptional activators to initiate 
transcription. A close example of this would be the small molecule chetomin, which 
perturbs the structure of the CH1 domain. Although it was identified as an inhibitor of 
HIF-1α mediated transcription, it has been shown to inhibit the activity of a Gal4-
Stat2 construct.63 
From a biological point of view, the potential for specificity for a single gene 
may be even more remote, but such exacting selectivity may be unnecessary. Because 
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any given activator or coactivator will probably be necessary for more than a single 
target gene, any intervention that targets the transcriptional machinery may directly 
affect many genes. This lack of perfect specificity for a single gene may not turn out 
to be a problem, as many activators regulate functionally related clusters of genes. 
Indeed, it may be beneficial. Recent developments with therapeutic combinations64,65,66 
support the idea that affecting several related systems is a more effective way to treat 
pathology that targeting a single cellular event – such as the activity of a single 
kinase, or the expression of a single gene. The redundancy of signaling networks (and 
the adaptability of pathologies such as cancer) mean that individual perturbations can 
often be overcome.  
D.3. Initial Advances in the Design of Synthetic Activation Domain 
Mimics
Initial work in the design of synthetic agents that modulate transcription has 
focused largely on the design of synthetic activators. For these to be effective, they 
must possess the same minimal function as transcriptional activator proteins – namely, 
a DNA binding domain and a transcriptional activation domain. Non-biomolecule 
DNA binding domains have been develop using large polyamides made up of 
imidazole, pyrrole, and hydroxypyrrole subunit that are designed to bind to the minor 
groove of double-stranded DNA in a sequence specific manner.67,68
Most of the artificial activation domains known are peptides, or are based on 
peptide like polymers. Artificial activators are often identified by screening against 
known binding partners of transcriptional activators. For example, the Kodadek lab 
was able to identify potent artificial peptidic activation domains that function in yeast 
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by carrying out phage display against Gal80, a repressor protein that is known to bind 
to the yeast activator Gal4.69 This same lab has also identified potent peptoid based 
transcriptional activators based on a screen against the KIX domain of CBP.70 In 
another example, peptides were screened for the ability to bind to the yeast 
coactivator Med15.71 In all of these example, peptides or peptoids that functioned as 
activation domains were identified, but success at identifying small molecules that act 
as activation domain mimics has been more rare.
D.4. Small Molecule Inhibitors of Transcription
Although a handful of small molecules that target activator-coactivator 
interactions have been identified in spite of the difficulties outlined in section D2, 
these molecules have mostly been developed using screens against the well 
characterized coactivators CBP and p300. For example, KG-501 was identified 
through an NMR based screen, in which the ability of a library of molecules to 
interact with the KIX domain of the coactivator CBP was assessed.14 This molecule 
inhibits the CREB-CBP interaction with a Ki of approximately 90 µM, and interferes 
with transcription of a luciferase reporter under the control of CREB and the 
production of NR4A2 (a CREB target gene) mRNA, both at concentrations between 5 
and 10 µM. The fungal metabolite Chetomin63 was also identified as a potential 
transcripional inhibitor based on its ability to interfere with the interaction between a 
minimal HIF-1α binding region of the CH1 domain of CBP, and a 41 residue peptide 
derived from the activation domain of  HIF-1α. Although chetomin is highly effective 
at disrupting this interaction and has prominant effects on the ability of Gal4- HIF-1α 
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to activate a reporter gene at concentrations as low as 5nM, these activity appears to 
be caused by the ability of chetomin to disupt the structure of CBP.
There are examples of inhibitors discovered using methods that do not depend 
on detailed knowledge of a coactivator. ICG-001,  an inhibitor of β-catenin mediated 
transcription, was identified from a screen against β-catenin activity in a reporter 
system. ICG-001 reduces expression of a β-catenin controlled reporter gene, and the 
transcription of known β-catenin target gene survivin at concentrations as low as 10 
µM.15 The molecule dubbed 'wrenchnolol' was optimized from a lead molecule 
identified using a high throughput screen in which the ability of compounds to kill 
erbB2 overexpressing cells was assessed.  Wrenchnolol appears to reduce erbB2 
protein levels at 7 µM, and GST-pulldowns indicate that one of the cellular proteins 
that wrenchnolol interacts with is the putative ESX coactivator Med23.16 Although 
these molecules validate the potential of small molecules to act as transcriptional 
inhibitors, they do not provide a generalizable design rationale.
15
Figure I-5. Small molecule transcriptional inhibitors identified from high throughput 
screens. (a) KG-501 also interacts with CBP, but reduces CREB driven transcription. 
(b) Chetomin, which acts by destabilizing the CH1 domain of p300 (c) ICG-001 
which interferes with β-catenin mediated transcription by blocking the activator 
binding site on CBP. (d) Wrenchnolol affects erbB2 expression by blocking a putative 
interaction between the transcription factor ESX and Med23. 
D.5. The Development of Isoxazolidine-Based Activation Domain Mimics  
Based on the model of activation domains as short, amphipathic sequences 
responsible for recruiting coactivators to the promoter, previous research in the Mapp 
lab identified isoxazolidines, such as I-1 as potential activation domain mimics. These 
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molecules present amphipathic functionality in an approximately helical arrangement. 
In order to test the ability of these molecules to act as activation domain mimics, they 
were attached to a known ligand of the glucocorticoid receptor ligand binding domain 
(GR LBD). This allowed the isoxazolidine I-1 to activate transcription of reporter 
genes controlled by a Gal4-GR LBD fusion protein in a dose dependent manner in 
mammalian cells.72 
In support of their activity as activation domain mimics, these molecules 
appear to interact with the coactivator CBP in a manner similar to that of the natural 
activation domains MLL and Jun. Chemical shift perturbation of 1H-15N HSQC 
spectra of the KIX domain of CBP upon addition of I-2 indicate that this molecule 
interacts with a large subset of the residues that interact with MLL and Jun, in effect, 
binding to the same site on CBP.73 The ability of these molecules to mimic the 
interactions of natural TADs indicated that they would be effective as scaffolds for the 
development of transcriptional inhibitors. 
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Figure I-6. Development of an isoxazolidine based TAD. Isoxazoldine-DBD 
conjugate I-1 (DBD = oxidized dexamethasone) activates transcription in a dose 
dependent manner in mammalian cells. I-2 interacts with the same region of the KIX 
domain of the coactivator CBP as the natural activation domains MLL and Jun. 
Figures from Buhrlage, S.J. et al. ACS Chemical Biology 2009, 4, 335-345 and Rowe, 
S. P. et al J. Am. Chem. Soc.2007, 129, 10654-10655. Used with permission.
E. The Regulation of the ErbB2 oncogene by ESX and the Role of the ErbB2 
Protein 
E.1. Biological Role and Clinical Relevance of the ErbB2 Protein
The model system chosen to test our rationale for inhibitor design was ESX 
driven overexpression of erbB2. ErbB2 (Her2) is a transmembrane tyrosine kinase 
growth receptor that is overexpressed in approximately 25% of breast cancers,54 
where it has been shown to drive an aggressive phenotype marked by more rapid 
metastasis and shorter life expectancy than breast cancers which do not over-express 
erbB2.56,74,75 Furthermore, erbB2 over-expressing (erbB2+) cancer cells are known to 
undergo growth arrest and cell death if erbB2 expression is suppressed.76,77,78  
ErbB2 drives oncogenesis through its interactions with other member of the 
erbB family of growth factor receptors. In addition to erbB2 this family also includes 
erbB1 (EGFR), erbB3 and erbB4. These receptors undergo ligand induced 
dimerization, forming hetero- or homo- dimers that undergo a series of 
autophosphorylation events, followed by transphosphorylation that allows the dimer 
to initiate cellular signaling programs.79 ErbB1 and erbB3 both have known ligands 
that induce them to form dimers. In contrast, erbB2 is putatively ligandless.75 This is 
supported by the observation that the conformation of the non-functional ligand 
binding domain of erbB2 is similar to the conformation of activated, ligand-bound 
domain of erbB1.80 Perhaps because of this, erbB2 occupies a unique place in the 
erbB family. ErbB2 is known to form active heterodimers with both erbB1 and erbB3, 
which have been shown to strongly activate the Ras/Raf/MAPK (erbB2/erbB1)81 and 
PI3K/Akt (erbB2/erbB3)82 pathways. Although erbB1/erbB1 and erbB1/erbB3 dimers 
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are also possible, erbB2 appears to be the preferred dimerization partner for both of 
the proteins. ErbB2 containing heterodimers initiate stronger signaling responses, and 
are more resistant to endocytosis and proteolysis.83,84,75 
The role of erbB2 in the initiation and progression of cancer has been 
evaluated both phenotypically and biochemically. Clinically, patients with erbB2 
overexpressing tumors have shorter life expectancy, are more likely to develop 
resistance to their chemotherapy and to experience relapse than patients with non 
erbB2+ breast cancers.74,85 In both murine and cell culture models, induction of erbB2 
overexpression is sufficient to transform previously non-tumorigenic cells.86,75 
Subsequently, cessation of erbB2 overexpression either leads cells to revert to an 
untransformed phenotype,86 or to growth inhibition and death of erbB2+ tumors.87,78  
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Figure I-7. ErbB2 is the preferred dimerization partner for erbB signaling. ErbB2 
forms heterodimers with erbB1 and erbB3 that activate Ras and PI3K/Akt signaling 
pathways.  
E.2. Regulation of ErbB2 Transcription
The primary regulator of erbB2 overexpression appears to be the ets family 
transcriptional activator ESX.18,17,19 The minimal activation domain of ESX that 
functions in a reporter assay  when fused to a Gal4 DNA binding domain is ESX129-
159.38 Within this region, mutagenesis indicates that residues 137-SWIIELLE-144 
appear to be a hotspot which are essential to activity. Mutation of either Trp138, or 
either the leucines or isoleucines abrogated interaction with coactivator mediator 
subunit 23 (Med23) a putative target of ESX. Analysis of the NOE spectrum of this 
region indicates helicity,38 and mapping the region 137-SWIIELLE-144 on to a helical 
wheel produces an amphipathic display, with a clearly defined hydrophobic surface 
for protein-protein interactions. As is discussed in later chapters, small molecules 
which mimic the hydrophobic surface of this activation domain are effective at 
curbing ESX driven erbB2 expression in erbB2+ cancer cells. 
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Figure I-8. The transcriptional activator ESX regulates transcription of erbB2. There 
is evidence that interaction between the TAD of ESX and the mediator subunit Med23 
plays an important role in this process. The key region of the activation domain of 
ESX is thought to be the eight residue section 137-SWIIELLE-144. This region is 
putatively helical, and mapping it onto a helical wheel suggests the presence of a 
nonpolar surface for interacting with coactivator proteins such as Med23.     
F. Research Misconduct in the Sciences
F.1. Misconduct Defined
 
Science, as a cumulative and often cooperative undertaking, relies on a 
reasonable amount of trust between different researchers. In the absence of such trust, 
the exchange of information and the dissemination of results that are essential to the 
present research paradigm become suspect and ultimately useless. Accordingly, 
funding agencies actively discourage research misconduct. The Office of Research 
Integrity, which is also responsible for investigating alleged misconduct and 
administering penalties to offenders, defines research misconduct in terms of 
falsification, fabrication, and plagiarism.88 
Research  misconduct  means  fabrication,  falsification,  or  plagiarism  in 
proposing, performing, or reviewing research, or in reporting research results. 
(a)  Fabrication is making up data or results and recording or reporting them. 
(b)  Falsification is manipulating research materials, equipment, or processes, 
or changing or omitting data or results such that the research is not accurately 
represented  in  the  research  record.  (c)  Plagiarism is  the  appropriation  of 
another person's ideas, processes, results, or words without giving appropriate 
credit. (d) Research misconduct does not include honest error or differences of 
opinion. 
Although these definitions are generally used when misconduct is discussed, 
they are not comprehensive. They are not generally interpreted to include activities 
such  as  sabotage,  the  misrepresentation  of  experimental  protocols,  or  the  use  of 
research designs that are known to be inadequate or inappropriate.  
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F.2. Occurrence of Misconduct
There are numerous well-document and highly publicized cases of research 
misconduct. These include extensive forgeries such as those of Hendick Schon at Bell 
labs,89 in which Dr. Schon was found to have fabricated the data used in a series of 
papers published in several journals, including both Nature and Science. A more 
recent example of misconduct comes from a research lab at Columbia University,90,23 
which involved some 21 counts of, fabrication and falsification by a graduate student 
and lead to the retraction of 6 papers. Another recent example, albeit one that does not 
fit the technical definition of misconduct, took place at the University of Michigan.22 
In this case, it was determined that a post-doctoral researcher had been sabotaging a 
graduate students research for a period of several months, with total damages 
estimated at approximately $70,000. There is an emerging consensus in the literature 
that these cases represent only the 'tip of the iceberg' and that there are many instances 
that go unreported.20,21,91
The prevalence of research misconduct has been evaluated by administering 
anonymous surveys, in which researchers are asked about their own conduct and that 
of their colleagues. Although there is variation in the estimated frequency of 
misconduct depending on the definitions and methods used, the data from surveys 
consistently indicate a surprisingly high rate of questionable or inappropriate conduct. 
In an analysis of approximately 3,000 NIH funded researchers, Martinson et al.91 
determined that although only 0.3% of their respondents admitted to 'Falsifying or 
cooking research data,' 15% admitted to 'dropping observations or data points from 
analyses based on a gut feeling that they were incorrect,' and 13.5% admitted to using 
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inadequate or inappropriate research designs. A meta analysis of the literature on 
misconduct20 concludes that the falsification rates reported by Martinson are probably 
artificially low, in part because the language used asks specifically about falsification 
and fabrication (which researchers are reluctant to admit to) rather than particular 
behaviors that fall under these categories. The overall results from the meta-analysis 
indicate that approximately 2% of respondents admit to having falsified or fabricated 
at least one piece of data themselves, while 15% had knowledge of a coworker who 
has done so. Frequency of other questionable practices (such as using inappropriate 
research designs, or reporting intentionally incomplete methodological data) were 
approximately 30% for self-admission, and 70% for observed behavior of coworkers. 
At this point, the causes of the discrepancy between the self-reported rates of 
misconduct and the rates of known or observed misconduct are largely speculative. In 
addition to the obvious explanation – that researchers are reluctant to admit to 
misconduct even under anonymous conditions – it is possible that the rates of known 
or observed misconduct include events that are suspected but unproven, or multiple 
reportings of single events or persons known to many researchers. Despite this caveat, 
data such at these indicate that researchers often act in ways that damage the implicit 
trust and openness that is part of the ethos of modern science.   
G. Summary of Thesis
In Chapter II, I discuss advances that target the activity of transcriptional 
activator proteins by using small molecules designed to mimic a particular activation 
domain, thereby interfering with the ability of the native transcriptional activator 
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protein to initiate transcription of its target genes. The model system in which these 
advances are demonstrated is transcription of the oncogene erbB2, which is a well 
established driving force in breast cancers. Chapter III describes the development and 
application of a strategy that overcomes some of the inherant potency and selectivity 
limitations of using a small molecule to target the protein-protein interactions that 
regulate transcription. As a meta-research issue, Chapter IV is concerned with the 
development and implementation of a workshop designed to provoke discussion of 
good research practices among incoming graduate students. Appendix A details initial 
work on a project that will use peptidomimetics to inhibit the activity of NFκβ subunit 
p65, a second transcriptional activator protein which plays a key role in both 
inflammation and cancer progression. Finally, Appendix B describes the development 
of a novel methodology for the syntheses of alleneamides, which provide a versatile 
precursor to densely functionalized heterocycles such as those used for the design of 
small molecules that target components of the transcriptional machinery.      
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Chapter II
Inhibition of ErbB2(Her2) Expression with Small Molecule Transcription Factor 
Mimicsa
A. Chapter Overview
Developing molecules that interfere with the protein-protein interactions that 
initiate transcription using methods such as high throughput screening, or structure 
guided design based on crystallographic data has proven difficult, owing to the poorly 
understood and complex nature of these interactions.1,2 Furthermore, it has been difficult 
to draw generalizable lessons from the rare examples identified through those 
approaches, because most of these successes3,4,5,6 have been had with activators for which 
at least one protein-protein interaction is well characterized, which is not the case for 
most transcriptional activators.7 
Based on the prevailing model that transcriptional activation domains tend to form 
alpha helices when interacting with their coactivator targets,2,8 we  hypothesized that it 
would be possible to use a small molecule scaffold that is known to act as a general 
transcriptional activator, and turn it into a transcriptional inhibitor by tailoring its 
a Parts of this chapter appear in Lee, L. W.; Taylor, C. E. C.; Desaulniers, J. P.; 
Zhang, M.; Hojfeldt, J. W.; Mapp, A. K. Inhibition of ErbB2(Her2) expression with 
small molecule transcription factor mimics. Bioorganic & medicinal chemistry  
letters 2009, 19, 6233-6236.
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functionality to more closely resemble a specific activation domain as depicted in Figure 
II-1. An isoxazolidine scaffold previously shown to mimic the activity and binding 
profile of a transcriptional activation domain9,10,11 was altered to mimic that of the 
transcription factor ESX, which regulates expression of the erbB2 oncogene.12,13,14 When 
used against erbB2 overexpressing cancer cells, these transcriptional inhibitors lead to 
decreased expression of the cell surface growth receptor ErbB2 (Her2) and curb the 
proliferation of erbB2 overexpressing cells. These results demonstrate a versatile 
rationale for the design of small molecule transcriptional inhibitors. 
Figure II-1. The modular nature of activator proteins. The transcriptional activation 
domain (TAD) of an activator protein is responsible for establishing the protein-protein 
interactions that lead to recruitment of RNA Polymerase II, and transcription of the 
activator's target gene. Small molecules that mimic key regions of the TAD should 
interfere with its ability to recruit coactivators and initiate transcription. 
B. Background
B.1. Transcriptional Activation Domains
Transcriptional activator proteins are minimally comprised of a DNA binding 
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domain (DBD)– which recognizes the activators cognate DNA sequence on the promoter 
– and a transcriptional activation domain (TAD) – which mediates the protein-protein 
interactions necessary to recruit the transcriptional machinery and initiate transcription15 
(Fig II-1a). The largest class of these activation domains, the 'acidic' or 'amphipathic' 
class, is characterized by interspersed acidic and hydrophilic residues.1,2 Although these 
domains are often unstructured in solution, they are thought to form amphipathic alpha-
helices in order to interact with their coactivator targets. The biologically relevent 
activator-coactivator interactions are a matter of continuing discussion in the literature,2 
but it appears that individual activators must interact with multiple proteins in a particular 
order to facilitate transcription.16,17,18 In addition, coactivators generally interact with more 
than one transcriptional activator,19,7,20 and some coactivators, such as the paralogs CBP 
and p300, are known to interact with more than a hundred different activators.1 The 
multi-partner binding profiles of both activators and coactivators limit the utility of 
binding based assays for screening, and highlight the potentil utility of a design approach 
that is not based on a single putative activator-coactivator interaction.
B.2. Existing Small Molecule Transcriptional Inhibitors
Excluding ligand activated systems such as nuclear receptor mediated 
transcription, there are very few examples small molecule transcriptional inhibitors.
1,3 Most of the molecules identified are the results of high throughput screens, and are 
large, relatively planar, lipophilic molecules (Figure II-2). One example is ICG-001,4  an 
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inhibitor of β-catenin mediated transcription that targets an activator binding site on CBP. 
ICG-001 reduces expression of a β-catenin controlled reporter gene, and the transcription 
of the known β-catenin target gene survivin at concentrations as low as 10 µM. KG-5016 
also targets CBP, and was identified through an NMR based screen, in which the ability 
of a library of molecules to interact with the KIX domain of the coactivator CBP was 
assessed. This molecule inhibits the CREB-CBP interaction with a Ki of approximately 
90 µM, and interferes with transcription of a luciferase reporter under the control of 
CREB and the production of NR4A2 (a CREB target gene) mRNA, both at 
concentrations between 5 and 10 µM. A final example is the molecule dubbed 
'Wrenchnolol' by Uesugi and coworkers,21 which affects ESX mediated expression of 
erbB2. This molecule was optimized from the results of a high throughput screen for 
molecules that affected the viability of erbB2+ SkBr3 cells.  Wrenchnolol appears to 
reduce erbB2 protein levels at 7 µM, and GST-pulldowns indicate that one of the cellular 
proteins that wrenchnolol interacts with is the putative ESX coactivator Med23. Although 
these molecules validate the potential of small molecules to act as transcriptional 
inhibitors, they do not provide a generalizable design rationale beyond that of screening 
small molecule libraries against known coactivator targets. 
35
Figure II-2 Small molecule transcriptional inhibitors identified from high throughput 
screens. (a) ICG-001 which interferes with β-catenin mediated transcription by blocking 
the activator binding site on CBP. (b) KG-501 also interacts with CBP, but reduces CREB 
driven transcription. (c) Wrenchnolol affects erbB2 expression by blocking a putative 
interaction between the transcription factor ESX and Med23. 
B.2. Using Small Molecule Transcriptional Activation Domain Mimics as 
Scaffolds for Transcriptional Inhibitors
In the course of developing small molecule-based transcriptional activators, this 
lab identified several amphipathic isoxazolidines that mimic the transcriptional activation 
domain (TAD) of endogenous amphipathic activators, the domain that interacts directly 
with the transcriptional machinery (Figure II-1). These isoxazolidines present a radial 
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display of functionality putatively similar to the active conformation of an activation 
domain. The molecule II-1 not only interacts with the KIX domain of CBP, a known 
target of transcriptional activators, but does so in a manner similar to the endogenous 
activators MLL and Jun (Figure II-3a).11 When localized to DNA, the isoxazolidine TADs 
up-regulate transcription in human cell culture up to 80-fold (Figure  II-3b).9 Thus, in the 
absence of a DNA-targeting moiety, we reasoned that this molecule could serve as a 
competitive inhibitor of activator-coactivator interactions. Furthermore, based on the 
shared structural characteristics of amphipathic activation domains, we hypothesized that 
this molecular scaffold could be used to develop inhibitors of specific activators 
responsible  for pathological developments within the cell. 
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Figure II-3. Development of an isoxazolidine based TAD. (a) NMR chemical shift 
perturbation experiments with II-1 and N15 labeled KIX domain indicate that II-1 
interacts with a region of KIX overlaps with those which interact with the endogenous 
activators MLL and Jun. (b) When II-1 is attached to a DNA-localizing moeity, it causes 
dose dependent upregulation of transcription in mammalian cell culture. Figures from ' 
Buhrlage, S.J. et al. ACS Chemical Biology 2009, 4, 335-345 and Rowe, S. P. et al J. Am.  
Chem. Soc. 2007, 129, 10654-10655. Used with permission.
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b)
a)
B.3. ESX Regulates Transcription of ErbB2
The activator chosen as a target for this study is ESX (ESE-1/ELF-3/ERT/Jen), an 
epithelial-specific transcriptional activator.22 Several lines of evidence suggest that the 
ESX is a key regulator of ErbB2 expression. This include both correlative studies, in 
which ESX overexpression is seen to corellate with erbB2 levels in both primary tumors13 
and model systems.12,23 They also include more direct evidence, such as ESX knockdowns 
(Figure II-4a) in which shRNA knockdown of ESX reduces erbB2 levels, and attenuates 
the  growth (Figure  II-4b)  and migration  of  erbB2+ head and  neck cancer  cell  lines. 
Analysis  of  ESX  structure  and  activity  via  NMR and  alanine  scanning  mutagenesis 
indicates a key region neccesary for activation (137-SWIIELLE-144).21 The authors of 
this study propose that Tryptophan 138 is particularly important for ESX activity and that 
it is assisted by a combination of leucines and isoleucines which serve as the nonpolar 
face of the amphipathic binding surface.  The polar side chains are thought to form a 
solvent  exposed  face  that  orients  the  TAD against  its  contact  surface  on  coactivator 
targets.
39
Figure II-4. Effects of ESX knockdown on erbB2+ cells. (a) Knockdown of ESX reduces 
expression of erbB2 and EGFR (erbB1) in Cal27 cells, an EGFR+ and erbB2+ head and 
neck cancer cell line. (b) Knockdown of ESX also reduces the proliferation of Cal27 cells 
compared to a scrambled shRNA.  
B.4. ErbB2 Function and Relevance  
ErbB2 is a transmembrane tyrosine kinase that  is overexpressed in approximately 
25% of breast cancers (erbB2+),24 where it drives an aggressive phenotype marked by 
more rapid metastasis and shorter patient life expectancy than breast cancers that do not 
overexpress erbB2.25,26,27,28 Unlike the other three members of the erbB family, a ligand for 
the extracellular domain of erbB2 has not been identified.28 Instead, the extracellular 
domain of erbB2 appears to adopt a conformation that resembles the ligand- bound state 
of the other receptors.29 Perhaps because of this, erbB2 is the preferred dimerization 
partner for erbB1 and erbB3.30,31 The resulting dimers strongly activate signaling cascades 
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responsible for cell growth and survival, such as the oncogenic RAS/MAPK and 
PI3K/Akt pathways.28 In particular, erbB2 and erbB3 appear to be extremely effective at 
inducing oncogenic signaling and tumor formation in a cooperative manner.31,32,33,34 In 
carcinoma cells which overexpress erbB2, reduction of erbB2 levels has been shown to 
cause growth arrest,35 reversal of transformation,36 or cell death.37 
Figure II-5. ErbB dimerization. Membrane integrated erbB2 forms ligand induced 
heterodimers with erbB3 or erbB1. These dimers initiate oncogenic signaling cascades 
within the cell. 
C. Design and Synthesis of Isoxazolidine Based ESX Mimics
C.1. Mimicking the ESX Activation Domain
 As noted previously, the active conformation of the the ESX activation is thought 
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to be alpha-helical.14 Mapping the putative hotspot of this activation domain onto a 
helical wheel (figure II-6b) suggests an amphipathic array of functionality similar to 
those found in other activation domains.7,38 In order to mimic this, we used a combination 
of aliphatic leucine or isoleucine like functionality and a large aromatic group in place of 
the tryptophan side chain. For many of the molecules, some polar functionality was 
retained. This was done because previous studies have suggested that transcriptional 
activators, and perhaps inhibitors, function best with an amphipathic mixture of polar and 
non-polar functional groups.11,39 
Figure II-6. The transcriptional activator ESX regulates transcription of erbB2.(a) Small 
molecules that mimic the activation domain of ESX should interfere with the activator's 
ability to recruit the transcriptional machinery and initiate transcription of erbB2. (b) The 
hotspot of the ESX activation domain is shown mapped on to a helical wheel. Polar 
residues are shown in black, while non-polar residues are shown in red to illustrate the 
amphipathic nature of the helix. 
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C2. Synthesis of ESX-Like Isoxazolidines.  
The general route used to synthesize the isoxazolidines shown in figure I-10 is 
summarized below in figure I-7. In brief, an isoxazoline is generated via a 1,3-dipolar 
cycloaddition. This isoxazoline is then functionalized at the C3 position using an 
organometallic nucleophile. The N2 position was functionalized through either a 
reduction amination with the appropriate aldehyde, or a microwave assisted SN2 
reaction. Although this route was iterative rather than convergent, it had the advantages of 
being reliable, and of using many common intermediates that could be easily prepared on 
on large (>10g) scales.   
Figure II-7. General synthetic scheme for inhibitors. a) Notation used to describe 
positions on the isoxazolidine ring. b) The general synthetic scheme used to generate 
isoxazolidine inhibitors of erbB2 transcription. The initial 1,3-dipolar cycloaddition is 
followed by nucleophilic addition to C3, and then electrophilic functionalization of N2. 
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Figure II-8. Synthesis of II-2 and II-3
A specific example of this route II-2 is shown below. The route which followed 
the general synthesis depicted above was found to require the fewest 
protection/deprotection steps in this, and most of the other isoxazoldine syntheses. For 
those isoxazolidines with redox labile N2 substituents, a different general method was 
needed, owing to the tendency of the N2 functionalized intermediates to undergo side 
reactions during the final functional group changes. The synthesis of II-4 provides an 
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example of this alternative route. It was found that the unprotected N2 position was 
surprisingly stable to electrophilic reagents such as methanesulfonyl chloride. This 
stability was also noted with reagents intended to functionalize the N2 position, thus the 
necessity for microwave activation, even when electrophiles such as allyl or benzyl 
bromide were employed. It is postulated that this is primarily due to the inductive effect 
of the neighboring oxygen. Replacement of the C5 alcohol with an azide was followed by 
functional group manipulation, and finally with N2 functionalization using a reductive 
amination. Although slightly longer than the original route, this alternative provided 
access to isoxazolidines II-4 and II-5.   
Figure II-9 Synthesis of II-4 
45
Figure II-10. Isoxazolidines II-1 through II-11. The differences between each 
isoxazolidine and the generic TAD mimic II-1 are highlighted in red. 
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II-1 II-2 II-3
II-6II-5II-4
II-7 II-8
II-9 II-10 II-11
Table II-1. Effectiveness of isoxazolidines II-1 through II-11. Effects on curbing erbB2 
expression and inhibiting the proliferation of erbB2+ cells. + indicates that some effect 
was seen, but that either the effect was minimal, or it required very high (≥50 µM) 
concentrations. ++ indicates substantial effect at concentrations of 20 µM or less. Effects 
on erbB2 mRNA were assessed using qPCR (Dr. Lori Lee). Effects on erbB2 protein 
were assessed using either Western Blot analysis (Dr. Lori Lee) or ELISA. Effects on 
erbB2+ cells were assessed using a WST-1 viability assay. 
 
D. Evaluation of Isoxazolidine Based ESX Mimics
D.1. Effects on erbB2 Protein Levels
As shown in Table II-1, compounds were evaluated based on their ability to affect 
erbB2 mRNA production, protein levels, and their ability to attenuate the viability of 
erbB2+ SKBR3 cancer cells. These molecules include varying N2 substituents designed 
to better mimic the side chain functionality of tryptophan 138. They also include C5' 
variations and positional isomers of the early lead compound II-2. Because it has been 
shown that both peptidic and small molecule transcriptional activators are structurally 
47
permissive,40,41 we chose to investigate this for our inhibitors. These results were 
inconclusive. Although there may be some permissiveness, given the activity of II-3 and 
II-11, both II-9 and II-10 had noticeably lower activity, indicating that the similarities in 
the activities of positional isomers are not as robust as those of activators.  
Initial results indicated that II-2 was the most effective of these molecules, and 
these results, in conjuction with the bench stability and ease of synthesis for this 
compound, lead to its being used for subsequent studies. Although some of the 
compounds which contained nitrogen in their N2 aromatic functional groups (such as II-6 
and II-4) were more intuitive tryptophan mimics, these compounds suffered from 
reduced activity and (in the case of indole containing compounds such as II-5 and II-6) 
reduced benchtop stability owing to the redox sensitive nature of the indole functional 
group. 
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Figure II-12. Effects of II-1 and II-2 on erbB2 expression. Compound II-1 has no effect 
on erbB2 expression in erbB2+ SkBr3 cells. In contrast, II-2 has a pronounced effect. 
Results are from an ELISA, in which SkBr3 cells (3x103 cell per well) were dosed with 
indicated amounts of compound for 16 hours, at which point the cells were lysed, and 
erbB2 and total protein concentration were assayed as described in section F. Error bars 
indicate standard deviation.  
The most reliable and most effective results were seen for II-2, and this 
compound was evaluated in more detail. Using an ELISA, II-2 was shown to reduce 
erbB2 levels (normalized in each well to total protein amount) in a dose dependent 
manner (Figure II-12). Similar results were seen in HNSCC cell lines by collaborators 
Dr. Pan and coworkers (Figure II-13) using western blot analysis. Additional support for 
the effects of II-2 comes from qPCR assays carried out by a colleague within the Mapp 
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lab (Dr. Lee, Figure II-13) which show erbB2mRNA levels reduced to approximately 
60% of control levels at 10uM of II-2. Throughout these experiments II-1 was used as a 
structurally related negative control. In contrast to II-2, it had no effect on erbB2 protein 
levels at concentrations as high as 100uM and minimal effects on erbB2 mRNA. Taken as 
a  whole, these results indicate that II-2 is effective at curbing overexpression of erbB2 in 
a variety of erbB2+ cancer cell lines. 
Figure II-13. Effects of II-2 on erbB2 protein and mRNA. Effects of II-2 as assessed by 
collaborating scientists. (a) II-2 reduces expression of erbB2 and erbB1 (EGFR) in 
SCC25 HNSCC cells. (Dr. Quintin Pan and  coworkers) (b) II-2 reduces erbB2 mRNA 
levels when compared to either a DMSO control or II-1. (Dr. Lori Lee).  
D.2. Effects on erbB2 Overexpressing Cells
As noted earlier, one of the reasons for choosing erbB2 as a model system was 
that reduction of erbB2 production or activity has been shown to cause growth arrest or 
death in erbB2+ cancer cells. We tested the ability of several potential ESX mimics, 
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including II-2 to exert similar effects. In keeping with its activity against erbB2 levels, 
II-2 was also effective against erbB2+ cancer cells.  The SkBr3 cell line was chosen for 
our experiments, because this line is known to express both erbB2 and erbB3, and to 
respond to ligands that activate this dimer (such as neuregulin) with increased PI3K/Akt 
signaling, making it a useful approximation of the expected environment in primary 
erbB2+ cancer cells.42 Isoxazolidine II-2 inhibited the growth of SKBR3 cells with in a 
dose dependent manner, with an IC50 of 14 ± 1 µM, while isoxazolidine II-1 was 
ineffective at concentrations up to 100 µM. 
Figure II-14. II-2 reduces the viability of erbB2+ SkBr3 cells. II-2 reduces the viability 
of erbB2+ SkBr3 cells in a dose dependent manner, while negative control II-1 has 
minimal effect at similar concentrations. These data are from SkBr3 cells (3x103 per well) 
dosed for 24 hours with compound as indicated. Viability measurements were obtained 
using WST-1 reagent as described in section F. Error bars indicate 1 standard deviation.  
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Figure II-15. Comparison of the effects of II-2 (SkBr3 vs MCF-7).Comparison of the 
effects of II-2 on erbB2+ SkBr3 cells vs. its effects on  estrogen driven MCF-7 breast 
cancer cells. These data are from SkBr3 and MCF-7 cells (3x103 per well) dosed for 24 
hours with compound as indicated. Viability measurements were obtained using WST-1 
reagent as described in section F. Error bars indicate 1 standard deviation. 
  
Figure II-16. Comparison of the effects of II-2 (SkBr3 vs. IMR90). Comparison of the 
effects of II-2 on erbB2+ SkBr3 cells vs. its effects on non-tumorigenic IMR90 cells. 
These data are from SkBr3 cells (3x103 per well) dosed for 24 hours with compound as 
indicated. Viability measurements were obtained using WST-1 reagent as described in 
section F. Error bars indicate 1 standard deviation. 
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Table II-2. Comparison of the IC50s of II-2. Comparison of the IC50s of II-2 in each cell 
line, data is from the same experiments as figures II-14 through II-16. 
 
Isoxazolidine II-2 was also tested on the cell line MCF-7, which is driven by 
estrogen dependent signaling, rather than erbB activity, and in the non-tumorigenic 
fibroblast cell line IMR-90. In both cases the IC50 against these cell lines were reduced 
when compared to SKBR3 cells. This reduction amount to approximately 2-fold, which, 
while significant, may limit the long term applications of this approach. Similar issues 
with selectivity in both cellular toxicity43 and transcriptional selectivity5 are present in the 
literature. A detailed examination of the rationale for selectivity issues with 
transcriptional inhibitors, and a solution to this problem is discussed at length in the next 
chapter.  
E. Conclusions
Taken together,  these data  suggest that  isoxazolidine  II-2 is  a  much improved 
mimic of the transcriptional activation domain of ESX relative to the generic TAD mimic 
II-1,  validating our strategy for using an artificial TAD as a scaffold for the design of 
transcriptional  inhibitors.   Treatment  of  ErbB2+  cancer  cells  with  isoxazolidine  II-2 
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reduces  erbB2  mRNA  and  protein  levels,  indicating  that  the  molecule  effectively 
interferes with the ability of ESX to activate transcription of erbB2. This molecule is also 
effective at attenuating the growth and viability of erbB2 overexpression cancer cells, 
which is consistent with the expected effects of an erbB2 transcriptional inhibitor. 
However,  II-2, like other small molecule transcriptional inhibitors, requires low 
micromolar concentrations for its cellular effects. This may be due to a combination of 
factors. Small molecules have much less surface area than is needed for most protein-
protein  interactions,  and  this  impacts  their  ability  to  inhibit  these  interactions  (ref). 
Transcriptional  activation  domains  in  particular  have  a  complex,  low  affinity  multi-
partner interaction profile that may make it difficult design high affinity small molecule 
inhibitors.   
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F. Supporting Information
F.1. Materials
Unless otherwise noted, starting materials were obtained from commercial sources 
and  were  used  without  any additional  purification.   CH2Cl2 and  THF were  dried  by 
passage  through activated  alumina  columns and degassed  by stirring  under  a  dry N2 
atmosphere.  Anhydrous DMF was purchased from Sigma-Aldrich (St. Louis, MO).  All 
reactions were performed under anhydrous conditions (N2 atmosphere) unless otherwise 
noted.  Et3N was distilled from CaH2. Purification by flash chromatography was carried 
out with E. Merck Silica Gel 60 (230-400 mesh) according to the procedure of Still, 
Kahn, and Mitra.1 1H spectra were recording in CDCl3 at 400 MHz or 500 MHz and 13C 
NMR were recorded at 100 MHz or 125 MHz, Reverse-phase HPLC purifications were 
performed on a Varian ProStar 210 equipped with Rainin Dynamax UV-D II detector (λ = 
254 nm and λ = 214) using a C18 (8 x 100mm) Radial-PakTM cartridge with a gradient of 
0.1% TFA in H2O and CH3CN as the mobile phase.  Normal-phase HPLC purification 
was performed on Varian ProStar 210 equipped with Varian ProStar UV-VIS 345 detector 
using a SiO2 (25 x 100mm) Radial-PakTM cartridge in hexanes/EtOAc.  Molecules  II-1 
through  II-11 were  purified  by  reversed-phase  HPLC  prior  to  use  in  cell-based 
experiments.
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F.2. Cell proliferation assays:
SkBr3 and MCF-7 cells were seeded at 3x103 cells per well on 96 well plates in 
RPMI media supplemented with 2.5% fetal bovine serum (SkBr3) and 1:1 DMEM:F12 
supplemented  with  2.5%  fetal  bovine  serum  (MCF-7)  respectively.  After  24  hours, 
compound was added as a solution in DMSO (1% v/v final DMSO concentration). 24 
hours after dosing with compound, cells were treated with WST-1 reagent (Roche, Basel, 
Switzerland)  in  accordance  with  manufacturer’s  instructions.  Cell  proliferation  was 
calculated using DMSO-treated cells as 100%. IC50 values were calculated using equation 
S2  in Origin 7.0 (OriginLab Corporation, Northampton, MA). Figures shown are from 
experiments carried out in triplicate, with error bars indicating the standard deviation.
y = a + (b-a)/(1+(x-c)^d))  (equation S2)
Where a is equal to the maximum effect observed, b is equal to the minimum effect 
observed, c is equal to the IC50, and d is equal to the Hill slope. For determination of 
absolute IC50 minimum was set to 0% and maximum was set to 100%. 
F.3. ErbB2 and p-erbB2 ELISA:
ELISA assays were performed based on those published elsewhere. In brief, 
SkBr3 cells were plated in 10% FBS at 3000 cells per well in 96 well plates. After 
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adhering overnight, media was changed to 2.5% FBS and compound was added. After 16 
hours, media was removed carefully and cells were fixed and permeabilized with cold (-
20º C) methanol. The cells were then washed twice with TBST, blocked for 2 hours at 
room temperature with superblock (TBST solution from Pierce), incubated with the 
primary antibody overnight at 4º C (as a 1:500 solution in superblock). Cells were then 
washed twice more with TBST and incubate with secondary antibody for 2 hours at room 
temperature (as a 1:1000 solution in superblock). After being washed 3 times with TBST, 
Slow TMB (Pierce) was added to measure antibody levels in accordance with the 
manufacturer's instructions and the absorbance at 370 nm was measured. The cells were 
washed 3 more times with TBST and total protein levels were measured at 560 nm using 
BCA reagent (Pierce). ErbB2 and p-erbB2 levels were normalized to total protein 
concentration by calculating (A370-A370blank)/(A560-A560 blank), where the A370 
blank was from TMB treated cells not treated with a primary antibody, and the A560 
blank was BCA reagent in wells that did not have cells plated in them. The resulting 
ratios were then normalized to cells treated with DMSO.
F.4. Synthesis and Characterization of Compounds II-1 through II-11 and 
Intermediates. 
F.4a. Synthesis of Compounds II-2, II-3 and Intermediates Using the Scheme 
Shown in Figure II-8.
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3-methylbutanal oxime (II-S1)
Hydroxylamine hydrochloride (27.8 g, 400 mmol) and sodium carbonate (42.4 g, 400 
mmol) were combined in 400 mL toluene and heated to 70° C for 1 hour, with vigorous 
stirring. Reaction was cooled and isovaleraldehyde (27.7 mL, 250 mmol) was added 
slowly. The reaction was then heated to a light reflux (100° C ) and stirred for 4 hours 
until complete by TLC. The crude mixtures was cooled , filtered through a scintered glass 
frit, and washed with toluene. The filtrate was concentrated under reduced pressure and 
distilled at 100° C under reduced pressure using an aspirator to yield II-S1 a pale yellow 
oil (25.3 g, 78%). 
(3-isobutyl-4,5-dihydroisoxazol-5-yl)methanol (II-S2)
Oxime II-S1 (2.0 g, 20 mmol) and allyl alcohol (10.8 mL, 160 mmol) were combined in 
400 mL toluene in a foil wrapped round bottom with vigorous stirring, cooled with an ice 
water bath. A 6% solution of sodium hypochlorite ('Chlorox bleach', 62 mL, 50 mmol 
hypochlorite) was added dropwise. The crude reaction was partitioned between toluene 
and water, and the organics were concentrated under reduced pressure and purified by 
column chromatography to yield isoxazolidine II-S2 as a yellow oil (3.1 g, 60%) 
3-allyl-3-isobutylisoxazolidin-5-yl)methanol (II-S3)
Boron Triflouride Etherate (1.85 mL, 14.7 mmol) was added to isoxazoline II-S2 (0.771 
g, 4.91 mmol) in  50 mL dry tetrahydrofuran under nitrogen at -78° C. After 15 minutes, 
allylmagnesium chloride (2M in hexanes, 7.35 mL, 14.7 mmol) was added dropwise. The 
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reaction was monitored via TLC and quenched at -78° C with 1:1 mixture of methanol 
and saturated acqueous ammonium chloride. The crude mixture was partitioned with 
water, and the organics were concentrated under reduced pressure and purified by column 
chromatography to yield isoxazolidine II-S3 (0.97 g, 73%). 
3-allyl-5-(((tert-butyldimethylsilyl)oxy)methyl)-3-isobutylisoxazolidine (II-S4)
Tert-butyldimethylchlorosilane (0.772 g, 5.1 mmol) was added to a solution of 
isoxazolidine II-S3 (0.72 g, 4.3 mmol) and imidazole (0.58 g, 8.5 mmol), in 40 mL dry 
tetrahydrofuran under nitrogen. Reaction was stirred at room temperature until 
completion. The crude mixture was partitioned with water, and the organics were 
concentrated under reduced pressure and purified by column chromatography to yield 
isoxazolidine II-S4 (5 g, >90%). 
 
2-([1,1'-biphenyl]-4-ylmethyl)-3-allyl-3-isobutylisoxazolidin-5-yl)methanol (II-S5)
Isoxazolidine II-S4 (0.95 g, 3 mmol), biphenylmethyl bromide (4.5 g, 18 mmol), and 
diisopropylethyl amine (3.2 mL, 18 mmol) where combined in 30 mL of 
dimethylformamide. This solution was heated using a conventional microwave in 10 
second pulses at 20% power until the reaction was complete by TLC. The crude mixture 
was partitioned with water, and the organics were concentrated under reduced pressure 
and passed through a short column of silica to remove as much DMF as possible. The 
resulting mixture was carried on crude. 
Crude isoxazolidine was dissolved in 15 mL of 1M tetrabutylammonium fluoride in 
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tetrahydrofuran and stirred at room temperature until the reaction was complete via TLC. 
The crude mixture was partitioned with water, and the organics were concentrated under 
reduced pressure and purified by column chromatography to yield isoxazolidine II-S6 
(0.51 g, 46%).
2-([1,1'-biphenyl]-4-ylmethyl)-3-allyl-5-(azidomethyl)-3-isobutylisoxazolidine (II-S6)
Methanesulfonyl chloride (0.17 mL, 2.5 mmol) was added to a solution of isoxazolidine 
II-S5 (0.30 g, 0.8 mmol) and triethylamine (0.32 mL, 2.5 mmol) in 8 mL 
dichloromethane at 0° C. After 2 hours, the crude mixture was partitioned with water, and 
the organics were concentrated under reduced pressure. The crude product was dissolved 
in 8 mL dimethylsulfoxide, and sodium azide (0.78 g, 12 mmol) was added. The resulting 
suspension was stirred vigorously and heated to 80° C overnight. The crude mixture was 
diluted with water. The organics were extracted with ethyl acetate and concentrated under 
reduced pressure, then purified by column chromatography to yield isoxazolidine II-S6 
(0.16 g, 48% over two steps). 
2-([1,1'-biphenyl]-4-ylmethyl)-5-(azidomethyl)-3-isobutylisoxazolidin-3-yl)ethanol 
(II-2 and II-3)
Osmium tetroxide (as a 2.5% solution in tert butanol, 0.4 mL, 0.04 mmol) was added to 
isoxazolidine II-S6 (0.16 g, 0.4 mmol) and N-methylmorpholine-N-oxide (0.94 g, 0.8 
mmol) in a mixture of tBuOH/THF/H2O (75%/20%/5%). Upon completion, reaction was 
quenched with sodium sulfite. The crude mixture was diluted with water. The organics 
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were extracted with ethyl acetate and concentrated under reduced pressure, then passed 
through a short column of silica to yield isoxazolidine which was carried on crude. 
Crude isoxazolidine was dissolved in 5 mL of 1:1 water:acetonitrile, and cooled to 
0° C. Sodium Periodate (0.17 g, 0.8 mmol) was added and the reaction was stirred for 30 
minutes. The reaction was partitioned with water, and the organics were concentrated 
under reduced pressure. This crude mixture was dissolved in methanol (5 mL) and 
sodium borohydride (16 mg, 0.42 mmol) was added at 0° C. After 15 minutes the crude 
mixture was diluted with water. The organics were extracted with ethyl acetate and 
concentrated under reduced pressure, then purified by column chromatography to yield 
isoxazolidine (120 mg), 76% yield over 3 steps as a 5:1 (II-2:II-3) mixture of 
diasteromers which was seperated via HPLC. 
F.4b. Synthesis of Compound II-1 and Intermediates Using the Scheme 
Shown in Figure II-8.
3-allyl-2-benzyl-3-isobutylisoxazolidin-5-yl)methanol (II-S11)
Run according to the protocol for II-S5 with isoxazolidine II-S4 (0.625 g, 2 mmol), 
benzyl bromide (1.37 g, 8 mmol), and diisopropylethyl amine (1.05 mL, 6 mmol), 
followed by 10 mL 1M tetrabutylammonium fluoride to yield isoxazolidine II-S11 (0.45 
g, 77% over two steps).
3-allyl-5-(azidomethyl)-2-benzyl-3-isobutylisoxazolidine (II-S12)
Run according to the protocol for II-S6, with isoxazolide II-S11 (205 mg, 0.71 mmol), 
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methanesulfonyl chloride (0.16 mL, 2.1 mmol), and triethylamine (0.27 mL, 2.1 mmol). 
Followed by sodium azide (900 mg, 14 mmol) to yield isoxazolidine II-S12 in (204 mg, 
>90% over two steps).
5-(azidomethyl)-2-benzyl-3-isobutylisoxazolidin-3-yl)ethanol (II-1)
Run according to the protocol for II-2, with isoxazoldine II-S12 (204 mg, 0.65 mmol), 
Osmium tetroxide (as a 2.5% solution in tert butanol, 0.65 mL, 0.07 mmol) and N-
methylmorpholine-N-oxide (152 mg, 1.3 mmol). This was followed by sodium periodate 
(214 mg, 1 mmol), and then followed by sodium borohydride (76 mg, 2 mmol) to yield 
isoxazolidine II-1 (130 mg, 63% over 3 steps as a 5:1 ratio of diastereomers that was 
seperated via HPLC).  
F.4c. Synthesis of II-8 and Intermediates Using the Scheme Outlined in 
Figure II-8. 
3-allyl-3-isobutyl-2-(4-(trifluoromethyl)benzyl)isoxazolidin-5-yl)methanol (II-S13)
Run according to the protocol for II-S5 with isoxazolidine II-S4 (200 mg, 0.64 mmol), p-
trifluorobenzyl bromide (0.51 mL, 3.2 mmol), and diisopropylethyl amine (0.34 mL, 1.9 
mmol), followed by 6.4 mL 1M tetrabutylammonium fluoride to yield isoxazolidine II-
S13 (170 mg, 74% over two steps).
3-allyl-5-(azidomethyl)-3-isobutyl-2-(4-(trifluoromethyl)benzyl)isoxazolidine (II-
S14)
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Run according to the protocol for II-S6, with isoxazolidine II-S13 (170 mg, 0.47 mmol), 
methanesulfonyl chloride (0.11 mL, 1.5 mmol), and triethylamine (0.19 mL, 1.5 mmol). 
Followed by sodium azide (305 mg, 4.7 mmol) to yield isoxazolidine II-S14 in (169 mg, 
>90% over two steps).
5-(azidomethyl)-3-isobutyl-2-(4-(trifluoromethyl)benzyl)isoxazolidin-3-yl)ethanol 
(II-8)
Run according to the protocol for II-2, with isoxazolidine II-S14(160 mg, 0.42 mmol), 
Osmium tetroxide (as a 2.5% solution in tert butanol, 0.42 mL, 0.04 mmol) and N-
methylmorpholine-N-oxide (100 mg, 0.85 mmol). This was followed by sodium 
periodate (135 mg, 0.63 mmol), and then followed by sodium borohydride (24 mg, 0.63 
mmol) to yield isoxazolidine II-8 (80 mg, 49% over 3 steps as a 5:1 ratio of 
diastereomers that was seperated via HPLC).  
F.4d. Synthesis of II-7 and Intermediates Using the Scheme Outlined in 
Figure II-8
3-allyl-3-isobutyl-2-(naphthalen-2-ylmethyl)isoxazolidin-5-yl)methanol (II-S15)
Run according to the protocol for II-S5, with isoxazolidine II-S4 (467 mg, 1.5 mmol), 2-
(Bromomethyl)naphthalene (1.65 mL, 7.5 mmol), and diisopropylethyl amine (0.78 mL, 
4.5 mmol), followed by 15 mL 1M tetrabutylammonium fluoride to yield isoxazolidine 
II-S15 (285 mg, 56% over two steps).
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3-allyl-5-(azidomethyl)-3-isobutyl-2-(naphthalen-2-ylmethyl)isoxazolidine (II-S16)
Run according to the protocol for II-S6, with isoxazolide II-S15 (270 mg, 0.80 mmol), 
methanesulfonyl chloride (0.18 mL, 2.4 mmol), and triethylamine (0.31 mL, 2.4 mmol). 
Followed by sodium azide (520 mg, 8 mmol) to yield isoxazolidine II-S16 in (132 mg, 
45% over two steps).
5-(azidomethyl)-3-isobutyl-2-(naphthalen-2-ylmethyl)isoxazolidin-3-yl)ethanol (II-7)
Run according to the protocol for II-2, with isoxazoldine II-S16 (120 mg, 0.33 mmol), 
Osmium tetroxide (as a 2.5% solution in tert butanol, 0.33 mL, 0.03 mmol) and N-
methylmorpholine-N-oxide (77 mg, 0.66 mmol). This was followed by sodium periodate 
(107 mg, 0.5 mmol), and then followed by sodium borohydride (19 mg, 0.5 mmol) to 
yield isoxazolidine II-7 (100 mg, 82% over 3 steps as a 5:1 ratio of diastereomers that 
was seperated via HPLC).  
F.4e. Synthesis of Compound II-6 and Intermediates Using the Scheme 
Shown in Figure II-8.
2-(2-(1H-indol-3-yl)ethyl)-3-allyl-3-isobutylisoxazolidin-5-yl)methanol (II-S17)
Isoxazolidine II-S4 (150 mg, 0.5 mmol), 3-(2-bromo-ethyl)-1H-indole (142 mg, 0.6 
mmol), and pottasium carbonate (0.21 g, 1.5 mmol) were combined in 2.5 mL of 
acetonitrile. This solution was heated  to 60°  C under nitrogen until no further 
conversion was observed by TLC. The crude mixture was partitioned with water, and the 
organics were concentrated under reduced pressure and chromatographed on silica to 
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yield isoxazolidine II-S17 (45 mg, 21%). 
3-allyl-3-isobutyl-2-(2-(1-tosyl-1H-indol-3-yl)ethyl)isoxazolidin-5-yl)methanol (II-
S18)
Isoxazolidine II-S17 (105 mg, 0.23 mmol) was dissolved in dry tetrahydrofuran and 
cooled to 0° C under nitrogen. Sodium hydride (12 mg of a 60% wt suspension in 
paraffin, 0.3 mmol) was added, followed by toluenesulfonyl chloride (50 mg, 0.27 
mmol). The reaction was quenched by the dropwise addition of water and partitioned 
between water and ethyl acetate. The crude mixture was dried using sodium sulfate and 
concentrated under reduced pressure. 
This mixture was then dissolved in 3 mL 1M tetrabutylammonium fluoride in 
tetrahydrofuran and stirred at room temperature until the reaction was complete via TLC. 
The crude mixture was partitioned with water, and the organics were concentrated under 
reduced pressure and purified by column chromatography to yield isoxazolidine II-S18 
(75 mg, 66% over two steps).
3-allyl-5-(azidomethyl)-3-isobutyl-2-(2-(1-tosyl-1H-indol-3-yl)ethyl)isoxazolidine (II-
S19) 
Run according to the protocol for II-S6, with isoxazolidine II-S18 (63 mg, 0.13 mmol), 
methanesulfonyl chloride (0.03 mL, 0.4 mmol), and triethylamine (0.05 mL, 0.04 mmol). 
Followed by sodium azide (85 mg, 1.3 mmol) to yield isoxazolidine II-S19 in (50 mg, 
74% over two steps).
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5-(azidomethyl)-3-isobutyl-2-(2-(1-tosyl-1H-indol-3-yl)ethyl)isoxazolidin-3-
yl)ethanol (II-6)
Run according to the protocol for II-2, with isoxazoldine II-S19 (50 mg, 0.1 mmol), 
Osmium tetroxide (as a 2.5% solution in tert butanol, 0.1 mL, 0.01 mmol) and N-
methylmorpholine-N-oxide (18 mg, 0.15 mmol). This was followed by sodium periodate 
(32 mg, 0.15 mmol), and then followed by sodium borohydride (6 mg, 0.15 mmol) to 
yield isoxazolidine II-6 (20 mg, 38% over 3 steps as a 5:1 ratio of diastereomers that was 
seperated via HPLC).  
F.4f. Synthesis of Compounds II-4, II-5, and Intermediates Using the General 
Scheme Shown in Figure II-9 
3-allyl-5-(azidomethyl)-3-isobutylisoxazolidine (II-S7)
Carried out as II-S6, with isoxazolidine II-S3 (880 mg, 4.4 mmol), methanesulfonyl 
chloride (0.91 mL, 13.2 mmol), and triethylamine (1.78 mL, 13.2 mmol). Followed by 
sodium azide (2.8 g, 44 mmol) to yield isoxazolidine II-S7 (377 mg, 38% over two 
steps).
tert-butyl 3-allyl-5-(azidomethyl)-3-isobutylisoxazolidine-2-carboxylate (II-S8)
Sodium hydride (208 mg of 60% weight suspension in paraffin, 5.2 mmol) was added to 
isoxazolidine II-S7 (377 mg, 1.9 mmol) in dry tetrahydrofuran at 0° C. The resulting 
mixture was stirred for 15 minutes, and then di-tert-butyl dicarbonate (1.74 g, 8 mmol) 
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and dimethylaminopyridine (324 mg, 2.65 mmol) were added. The reaction was stirred 
for 16 hours, after which it  was partitioned between water and ethyl acetate, and the 
resulting organics were dried (sodium sulfate), concentrated under reduced pressure and 
chromatographed on silica gel to yield isoxazolidine II-S8 (355 mg, 65%).
5-(azidomethyl)-3-(2-hydroxyethyl)-3-isobutylisoxazolidine-2-carboxylate (II-S9)
Run according to the protocol for II-2, with isoxazoldine II-S8 (330 mg, 1 mmol), 
Osmium tetroxide (as a 2.5% solution in tert butanol, 1.0 mL, 0.1 mmol) and N-
methylmorpholine-N-oxide (175 mg, 1.5 mmol). This was followed by sodium periodate 
(242 mg, 1.1 mmol), and then followed by sodium borohydride (34 mg, 0.9 mmol) to 
yield isoxazolidine II-S9 (200 mg, 56% over 3 steps). 
5-(azidomethyl)-3-(2-((tert-butyldimethylsilyl)oxy)ethyl)-3-isobutylisoxazolidine (II-
S10)
Trifluoroacetic acid (1.5 mL) was added to a solution of isoxazolidine II-S9 (190 mg, 0.6 
mmol) in dichloromethane (25 mL). When complete (by TLC) the reaction was quenched 
with saturated aqueous potassium carbonate, partitioned between water and ethyl acetate, 
and concentrated under reduced pressure. The crude mixture was then dissolved in dry 
tetrahydrofuran (6 mL) and imidazole (81 mg, 1.2 mmol) and tert-
butyldimethylchlorosilane (100 mg, 0.66 mmol) were added. Upon completion, the 
reaction was partitioned between water and ethyl acetate, and the resulting organics were 
dried (sodium sulfate), concentrated under reduced pressure and chromatographed on 
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silica gel to yield isoxazolidine II-S10 (151 mg, 76%). 
2-(2-(1H-indol-3-yl)ethyl)-5-(azidomethyl)-3-isobutylisoxazolidin-3-yl)ethanol (II-5)
Isoxazolidine II-S10 (50 mg, 0.15 mmol), 3-(2-bromo-ethyl)-1H-indole (224 mg, 1 
mmol), and triethylamine (0.064 mL, 0.5 mmol) where combined in 1 mL of N-Methyl-
2-pyrrolidone. This solution was heated using a conventional microwave in 10 second 
pulses at 20% power until the reaction was complete by TLC. The crude mixture was 
partitioned with water, and the organics were concentrated under reduced pressure and 
dissolved in 1 mL of 1M tetrabutylammonium fluoride in tetrahydrofuran and stirred 
until complete by TLC. The reaction was partitioned between water and ethyl acetate, and 
the resulting organics were dried (sodium sulfate), concentrated under reduced pressure 
and chromatographed on silica gel to yield isoxazolidine II-5 (12 mg, 22% of a 5:1 
diastereomeric mixture that was seperated using HPLC).
Preparation of 3-(4-phenylpiperazin-1-yl)propane-1,2-diol (II-S20)
1-phenylpiperazine (0.59 mL, 4 mmol), allyl bromide (0.34 mL, 4 mmol), and potassium 
carbonate (1.66 g, 12 mmol) were dissolved in DMF and stirred until the reaction was 
complete (TLC). The crude mixture was partitioned with water, and the organics were 
concentrated under reduced pressure and passed through a short column of silica to 
remove as much DMF as possible. The resulting mixture was dissolved in 20 mL of a 
mixture of tBuOH/THF/H2O (75%/20%/5%), Osmium tetroxide (as a 2.5% solution in 
tert butanol, 1.5 mL, 0.15 mmol) and N-methylmorpholine-N-oxide (0.70 g, 6 mmol) 
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were then added. The reaction was partitioned between water and ethyl acetate, and the 
resulting organics concentrated under reduced pressure and chromatographed on silica 
gel to yield 3-(4-phenylpiperazin-1-yl)propane-1,2-diol (249 mg, 18% yield over 2 steps). 
5-(azidomethyl)-3-isobutyl-2-(2-(4-phenylpiperazin-1-yl)ethyl)isoxazolidin-3-
yl)ethanol (II-4)
2-(4-phenylpiperazin-1-yl)acetaldehyde was prepared by adding sodium periodate (140 
mg, 0.65 mmol) to 3-(4-phenylpiperazin-1-yl)propane-1,2-diol (103 mg, 0.44 mmol) in 
4.4 mL of 1:1 water:acetonitrile. After 1 hour, the crude was partitioned between water 
and ethyl acetate, and the resulting organics concentrated under reduced pressure. This 
crude mixture was then dissolved in dichloromethane and added to isoxazolidine II-S10 
(30 mg, 0.09 mmol), sodium triacetoxyborohydride (74 mg, 0.35 mmol) and acetic acid 
(1 µL). After 6 hours, this reaction was partitioned between water and ethyl acetate, and 
the resulting organics concentrated under reduced pressure and dissolved in 1mL 1M 
tetrabutylammonium fluoride in tetrahydrofuran and stirred overnight. The reaction was 
partitioned between water and ethyl acetate, and the resulting organics were dried 
(sodium sulfate), concentrated under reduced pressure and chromatographed on silica gel 
to yield isoxazolidine II-4 (20 mg, 55% of a 5:1 diastereomeric mixture that was 
seperated using HPLC).  
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F.4g. Synthesis of Compound II-9 and Intermediates Using the Scheme 
Shown in Figure II-8. 
5-([1,1'-biphenyl]-4-yl)-3-allyl-3-isobutylisoxazolidine (II-S21)
Run according to the protocol for II-S2, with (1.53 mL, 11.7 mmol) oxime II-S1, (1.18g, 
11.7 mmol) p-bromostryene, and NaOCl (30 mL, 24 mmol, 6%). Carried on crude. 
According to the protocol for II-S3, crude isoxazoline fro the step above (3 g, 10.6 
mmol), allylmagnesium chloride (16 mL of a 2M solution, 32 mmol), BF3 (4 mL, 32 
mmol) were reacted together to yield isoxazoldine II-S21 (1.575 g, 41% over 2 steps). 
methyl 5-([1,1'-biphenyl]-4-yl)-3-allyl-3-isobutylisoxazolidin-2-yl)acetate (II-S22)
Run according to the protocol for II-S5 with isoxazolidine II-S21 (0.204 g, 0.63 mmol), 
methyl bromoacetate (0.82 mL, 8.6 mmol), and diisopropylethyl amine (0.56 mL, 3.2 
mmol) to yield isoxazolidine II-S22 (0.15 g, 60%).
5-([1,1'-biphenyl]-4-yl)-3-allyl-3-isobutylisoxazolidin-2-yl)ethanol (II-S23)
Diisobutylaluminium hydride (0.51 mL of a 1.5 M solution in toluene, 0.76 mmol) was 
added to a solution of isoxazolidine II-S22 (0.15 g, 0.38 mmol) in toluene at 0° C. After 1 
hr the reaction was partitioned between water and ethyl acetate, and the resulting organics 
were dried (sodium sulfate), concentrated under reduced pressure and chromatographed 
on silica gel to yield isoxazolidine II-S23 (0.10 g, 72%). 
5-([1,1'-biphenyl]-4-yl)-3-allyl-2-(2-azidoethyl)-3-isobutylisoxazolidine (II-S24)
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Run according to the protocol for II-S6, with isoxazolidine II-S23 (100 mg, 0.27 mmol), 
methanesulfonyl chloride (0.063 mL, 0.82 mmol), and triethylamine (0.11 mL, 0.82 
mmol). Followed by sodium azide (260 mg, 4 mmol) to yield isoxazolidine II-S24 (35 
mg, 33% over two steps).
5-([1,1'-biphenyl]-4-yl)-2-(2-azidoethyl)-3-isobutylisoxazolidin-3-yl)ethanol (II-9)
Run according to the protocol for II-2, with isoxazoldine II-S24 (31 mg, 0.08 mmol), 
Osmium tetroxide (as a 2.5% solution in tert butanol, 0.08 mL, 0.008 mmol) and N-
methylmorpholine-N-oxide (14 mg, 0.12 mmol). This was followed by sodium periodate 
(26 mg, 0.12 mmol), and then followed by sodium borohydride (6 mg, 0.16 mmol). Upon 
completion, the reaction was partitioned between water and ethyl acetate, and the 
resulting organics were dried (sodium sulfate), concentrated under reduced pressure and 
chromatographed on silica gel to yield isoxazolidine II-9 (15 mg, 47% over 3 steps).  
Synthesis of Compound II-10 and Intermediates Using the Scheme Shown in Figure 
II-8. 
4-bromobenzaldehyde oxime (II-S26)
Run according to the protocol for II-S1 with 4-bromobenzaldehyde (37.1 g, 200 mmol) 
hydroxylamine hydrochloride (20.9 g, 300 mmol) and sodium carbonate (33.8 g, 319 
mmol) to yield II-S26 (28.7 g, 72%)
(3-(4-bromophenyl)-4,5-dihydroisoxazol-5-yl)methanol (II-S27)
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Run according to the protocol for II-S2 with oxime II-S26 (14.9 g, 75 mmol), allyl 
alcohol (25.6 mL, 375 mmol), NaOCl (250 mL, 200 mmol, 6% solution) to yield II-S27 
(5.55 g, 29%).
3-(4-bromophenyl)-5-(((tert-butyldimethylsilyl)oxy)methyl)-4,5-dihydroisoxazole 
(II-S28)
Run according to the protocol for II-S3 with isoxazolidine II-S27 (5.55 g, 22 mmol), tert-
butyldimethylchlorosilane (3.62 g, 24 mmol) and imidazole (3.75 g, 55 mmol) to yield 
isoxazolidine II-S28 (7.14 g, 89%). 
3-([1,1'-biphenyl]-4-yl)-5-(((tert-butyldimethylsilyl)oxy)methyl)-4,5-
dihydroisoxazole (II-29)
Tetrakis(triphenylphosphine)palladium (80 mg, 0.07 mmol) was added to a solution of 
isoxazolidine II-S28 (604 mg, 1.42 mmol), phenylboronic acid (207 mg, 1.7 mmol) and 
potassium carbonate (784 mg, 5.7 mmol) in 14 mL 1:1 water:dimethoxyethane. The 
resulting mixture was heated to 80° C. Upon completion, the crude mixture was 
partitioned with water, and the organics were concentrated under reduced pressure and 
purified by column chromatography to yield isoxazolidine II-S29 (492 mg, 82%).
3-([1,1'-biphenyl]-4-yl)-5-(((tert-butyldimethylsilyl)oxy)methyl)-3-(2-
methylallyl)isoxazolidine (II-S30)
Run according to the protocol for II-S3 with isoxazoline II-S29 (2.5 g, 6.8 mmol), 2-
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methylallylmagnesium chloride (42 mL of an 0.5M solution, 21 mmol), BF3 (2.64 mL, 
21 mmol) to yield isoxazolidine II-S30 (656 mg, 23%).  
3-([1,1'-biphenyl]-4-yl)-5-(((tert-butyldimethylsilyl)oxy)methyl)-3-
isobutylisoxazolidine (II-S31)
Palladium (II) acetate (27 mg, 0.04 mmol) was added to isoxazolidine II-S30 (365 mg, 
0.86 mmol) dissolved in triethoxysilane (0.4 mL, 2.15 mmol) under nitrogen in a sealed 
tube. After 16 hours,  the crude mixture was partitioned with water, and the organics were 
concentrated under reduced pressure and purified by column chromatography to yield 
isoxazolidine II-S31 (180 mg, 49%).
3-([1,1'-biphenyl]-4-yl)-2-allyl-3-isobutylisoxazolidin-5-yl)methanol (II-S32)
Isoxazolidine II-S31 (0.18 g, 0.43 mmol), allyl bromide (0.3 mL, 3.4 mmol), and 
diisopropylethyl amine (0.56 mL, 3.2 mmol) were combined in 4 mL of 
dimethylformamide in a sealed microwave safe reaction vessel.  This solution was heated 
using a conventional microwave in 10 second pulses at 20% power, with four additional 
aliquots of allyl bromide added to replace any evaporation. The crude mixture was 
partitioned with water, and the organics were concentrated under reduced pressure and 
passed through a short column of silica to remove as much DMF as possible. The 
resulting mixture was carried on crude. 
Crude isoxazolidine was dissolved in 1.2 mL of 1M tetrabutylammonium fluoride 
in tetrahydrofuran and stirred at room temperature until the reaction was complete via 
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TLC. The crude mixture was partitioned with water, and the organics were concentrated 
under reduced pressure and purified by column chromatography to yield isoxazolidine II-
S32 (75 mg, 50% over two steps).
3-([1,1'-biphenyl]-4-yl)-2-allyl-5-(azidomethyl)-3-isobutylisoxazolidine (II-S33)
Run according to the protocol for II-S6, with isoxazolidine II-S32 (73 mg, 0.21 mmol), 
methanesulfonyl chloride (0.05 mL, 0.63 mmol), and triethylamine (0.08 mL, 0.6 mmol). 
Followed by sodium azide (195 mg, 3 mmol) to yield isoxazolidine II-S33 in (60 mg, 
76% over two steps).
3-([1,1'-biphenyl]-4-yl)-5-(azidomethyl)-3-isobutylisoxazolidin-2-yl)ethanol (II-10)
Run according to the protocol for II-2, with isoxazoldine II-S33 (46 mg, 0.12 mmol), 
Osmium tetroxide (as a 2.5% solution in tert butanol, 0.12 mL, 0.012 mmol) and N-
methylmorpholine-N-oxide (21 mg, 0.18 mmol). This was followed by sodium periodate 
(40 mg, 0.18 mmol), and then followed by sodium borohydride (9 mg, 0.24 mmol). Upon 
completion, the reaction was partitioned between water and ethyl acetate, and the 
resulting organics were dried (sodium sulfate), concentrated under reduced pressure and 
chromatographed on silica gel to yield isoxazolidine II-10 (21 mg, 46% over 3 steps).
3-([1,1'-biphenyl]-4-yl)-3-allyl-5-(((tert-butyldimethylsilyl)oxy)methyl)isoxazolidine 
(II-S34)
Run according to the protocol for II-S3 with isoxazoline II-S29 (0.96 g, 2.63 mmol), 
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allylmagnesium chloride (3.9 mL of a 2M solution, 7.9 mmol), BF3 (0.99 mL, 7.9 mmol) 
to yield isoxazolidine II-S34 (932 mg, 86%).  
3-([1,1'-biphenyl]-4-yl)-3-allyl-2-isopentylisoxazolidin-5-yl)methanol (II-S35)
Sodium cyanoborohydride (0.5 g, 8 mmol) was added to isoxazolidine II-S34 (0.67 g, 1.6 
mmol) and isovaleraldehyde (2.44 mL, 22.7 mmol) in 8 mL methanol and 0.15 mL water 
at 0° C, which was then brought to a pH of 2 using 1M hydrochloric acid. Upon 
completion, the crude mixture was partitioned with water, and the organics were 
concentrated under reduced pressure and passed through a short column of silica. The 
resulting mixture was carried on crude. 
Crude isoxazolidine was dissolved in 16 mL of 1M tetrabutylammonium fluoride 
in tetrahydrofuran and stirred at room temperature until the reaction was complete via 
TLC. The crude mixture was partitioned with water, and the organics were concentrated 
under reduced pressure and purified by column chromatography to yield isoxazolidine II-
S35 (527 mg, 90% over two steps).
3-([1,1'-biphenyl]-4-yl)-3-allyl-5-(azidomethyl)-2-isopentylisoxazolidine (II-S36)
Run according to the protocol for II-S6, with isoxazolidine II-S35 (495 mg, 1.35 mmol), 
methanesulfonyl chloride (0.32 mL, 4.1 mmol), and triethylamine (0.53 mL, 4.1 mmol). 
Followed by sodium azide (876 mg, 13.5 mmol) to yield isoxazolidine II-S36 (224 mg, 
43% over two steps).
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3-([1,1'-biphenyl]-4-yl)-5-(azidomethyl)-2-isopentylisoxazolidin-3-yl)ethanol (II-11)
Run according to the protocol for II-2, with isoxazoldine II-S36 (191 mg, 0.49 mmol), 
Osmium tetroxide (as a 2.5% solution in tert butanol, 0.49 mL, 0.05 mmol) and N-
methylmorpholine-N-oxide (90 mg, 0.75 mmol). This was followed by sodium periodate 
(160 mg, 0.75 mmol), and then followed by sodium borohydride (29 mg, 0.75 mmol). 
Upon completion, the reaction was partitioned between water and ethyl acetate, and the 
resulting organics were dried (sodium sulfate), concentrated under reduced pressure and 
chromatographed on silica gel to yield isoxazolidine II-11 (120 mg, 62% over 3 steps).
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Figure 17. II-1 1H NMR Spectrum
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Figure 18. II-2 1H NMR Spectrum
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Figure 19. II-3 1H NMR Spectrum
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Figure 20. II-4 1H NMR Spectrum
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Figure 21. II-5 1H NMR Spectrum
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Figure 22. II-6 1H NMR Spectrum
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Figure 23. II-7 1H NMR Spectrum
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Figure 24. II-8 1H NMR Spectrum
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Figure 25. II-9 1H NMR Spectrum
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Figure 26. II-10 1H NMR Spectrum
87
Figure 27. II-11 1H NMR Spectrum
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Chapter III
A Multi-Pronged Approach to Targeting Oncogenic Transcription
A. Chapter Overview
The aberrant function of a growing number of transcriptional activators is 
associated with the development and progression of human diseases such as cancer.1,2,3,4 
Molecules that interfere with the ability of transcriptional activators to control expression 
of their target genes have great promise as biochemical tools and therapeutics.  Activators 
regulate transcription through a complex network of interactions with transcriptional 
coactivator proteins. Blocking these interactions inhibits transcription. However, the 
affinity of these activator-coactivator interactions is modest (high nano- to low micro-
molar), possibly owing to the conformational flexibility of activation domains and the 
highly promiscuous nature of activator binding sites.5 In light of these issues, it is 
unsurprising that small- and large molecule inhibitors of these interactions require 
micromolar concentrations to exert their effects.6,7,8,9 It also highlights potential selectivity 
issues that may arise from blocking interactions with shared coactivator targets. 
The previous chapter described the development of a new class of small molecule 
transcriptional inhibitors that mimic transcriptional activation domains; this includes II-2 
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(figure III-1), an isoxazolidine that mimics the activation domain of the transcription 
factor ESX, and interferes with transcription of the ESX-regulated oncogene erbB2 at 
micromolar concentrations. Here we present a strategy that mitigates the potency and 
selectivity concerns of transcriptional inhibitors through a multi-pronged intervention 
against the erbB2 regulatory pathway. Specifically, II-2 is tested in combination with 
three other agents that target cellular events related to erbB2 activity, as shown in figure 
III-1. Two of these combinations exhibit synergistic increases in activity and selectivity, 
and correspondingly, reduce the doses of both agents required to cause 50% of maximal 
inhibition of mitochondrial viability in erbB2+ cancer cells. For example, combinations 
of II-2 and geldanamycin allow dose reductions of greater than 15-fold in both agents, 
while increasing selectivity for erbB2+ cells by as much as 30 fold when compared to 
individual agents. 
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Figure III-1. Rationale for synergy. Combinations of agents that target the transcription 
of erbB2, as well as the lifetime of the mature protein (Geldanamycin), or the ability of 
erbB2 containing dimers to initiate signaling (such as Lapatinib or Erlotinib) may be 
synergistically more effective that any of their individual components.     
B. Background
B.1. The Activitiy and Selectivity Concerns that Apply to Transcriptional 
Inhibitors
Although transcriptional inhibitors have been designed using a variety of 
scaffolds, from small molecules,7,8,9 to conformationally constrained and proteolytically 
resistant peptides,10,11 there are two recurring issues with these inhibitors – their activity 
and selectivity. Even in cases where peptides that directly mimic activation domains are 
used, such the HIF-1α mimic developed by the Arora lab, micromolar concentrations are 
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required for cellular activity. Because activators initiate transcription through a complex 
series of low affinity protein-protein interactions with regions of coactivators that are 
designed to accomodate a variety of non-homologous activation domains,12,13 there may 
be a limit to the affinity and biological activity that can be achieved using small 
molecules or short peptidomimetics. 
There are two potential selectivity issues for transcriptional inhibitors – the 
selectivity for a particular inhibitor-coactivator interaction, and selectivity for a effects on 
a particular gene. The first is an endemic problem for small molecule inhibitors of 
protein-protein interactions.14 Because the surface area of these interactions is typically 
much greater than the surface area of any reasonably sized small molecule it is likely that 
small molecule inhibitors will be less specific for a given target than the evolutionarily 
designed protein interaction partner. Additionally, because transcriptional activators 
interact with coactivator sites that are also targeted by other transcriptional activators,6,12 
inhibitors that interfere with the ability of one activator to bind to these sites are likely to 
have effects on the activity of other activators that target that same site. Furthermore, 
individual transcriptional activators regulate the expression of many different genes, 
which can include both related programs within the cell or feedback mechanisms that 
counteract and limit the primary function of the transcriptional activator.15 All of these 
factors indicate that even if it were possible to design transcriptional inhibitors which 
perfectly mimicked a single activator, such inhibitors would still have broad effects on 
cellular transcription.  
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B.2. Rationale for the Use of Multiple Agents in Combination 
The regulation of biological systems – especially those which are critical to the 
survival – is often complex and robust. Interventions that target these processes, such as 
the uncontrolled growth or suppression of apopotosis that characterize cancer cells, can 
be made irrelevent through redundant systems within the cell.16 A prime example of this 
is oncogenic signalling by erbB2 containing dimers on the cell surface. The kinase erbB2 
is the preferred dimerization partner for ligand receptors erbB1 and erbB3.17,18 In cell 
types where erbB1/erbB2 heterodimers are the primary signaling pair, kinase inhibitors 
that target erbB1 activity can initially reduce erbB2 signaling, but the cancer cells 
respond by increasing the steady state levels of erbB3 allowing pro-growth and anti-
apoptotic signals to continue in spite of kinase inhibition.19,20 In these studies, it has been 
shown that a combination of erbB2 knockdown and kinase inhibition is dramatically 
more effective than kinase inhibition alone. Similar results, in which the use of multiple 
agents to target related events within a cell achieve a 'synergistic' increase in effect, have 
been reported for other systems such as the use of Ribavirin and Disulfiram to target 
related processes in MRSA.21
B.3. Methods for Evaluating Synergy in Multi-Component Treatments 
There are two accepted and quantitative measures of synergy. One is an effect 
based method developed by Bliss and the other is the isobolographic method for 
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measuring dose reduction developed by Loewe and elaborated by Chou and others.22 The 
Bliss measurement is based on calculation of the statistically expected additive effects of 
two seperate agents (A and B) at particular doses. When combined, these two doses of A 
and B are expected to have an effect equal to (eA+eB)-(eA*eB), where eA and eB are the 
effects of A and B converted to a value between 0 and 1. For example, if a given dose of 
A kills 50% of a cell population (effect = 0.5), and a given dose of B also kills 50% of the 
same cell population, the statistically expected outcome of a combination of A and B at 
these same doses, would be to kill 75% of the cell population (50% of the whole 
population from A, and 50% of the remaining population from B). An example of the use 
of this method is a series of high throughput screen by Borisy and coworkers that 
identified a combination of fluconazole and phenazopyridine that is synergistically 
effective against fungal infection.23 
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Figure III-2. Bliss definition of synergy. A graphical representation of hypothetical 
examples being evaluated for synergy using the Bliss (multiplicative) definition. In both 
examples, the individual agents have an approximately 50% effect on their own. In the 
additive example, the combination of A and B, at the same doses which they were tested 
at individually, has a 75% effect. In the synergistic example, the combination has an 
effect greater than 75%. 
Although this method has the advantages of straighforward analysis, and of 
providing an intuitive readout, it suffers from the limitation that it does not rigorously 
account for the shape of the dose effect curves of the individual agents.24 Thus, in a null 
hypothesis case where agents A and B were the same compound (or enantiomers in a 
situation where this did not make a difference), and the dose effect curves had a greater 
than sigmoidal slope, it would be possible to see 'synergistic' effects merely because the 
total dose of compound had reached the exponential decay portion of the dose effect 
curve. Although this objection has lead to the development of the isobolographic methods 
described below, Bliss synergy is still widely used with the caveat that it is capable of 
producing false postives in some cases.25   
The isobolographic method for evaluating synergy is based on the principle of 
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dose equivalence.24 Tested combinations are compared to the null hypothesis that both 
components are actually the same agent (the results of which are considered to be 
additive). Dose-effect curves are evaluated for both individual agents, and for several 
fixed ratio combinations. Each combination has an IC50 for both of its components – 
because the amount of combination that produces 50% effect will have a particular 
amount of each component. The combination IC50s are then used to calculate dose 
fractions for each component. Thus, the dose fraction (of A) for a 1:1 combination of A:B 
would be the IC50 (of A, in the 1:1 combination) divided by the IC50 of A as a single 
agent. Repeating this process for B allows the combinations to be plotted on a 
isobologram. This chart effectively represents the degree of reduction in the doses 
required to produce 50% effect caused by combination use. The dotted line drawn 
between A and B indicates the line that would be produced in the case of the null 
hypothesis. Combinations which fall inside the region to the left of this line are 
considered synergistic, because they allow greater dose reduction that would be expected 
from simply using more of one of the single agents. The degree of synergy is given by the 
combination index (CI), which is simply the sum of the X and Y coordinates for any 
given combination. The CI of individual agents and additive combinations will equal one. 
A CI less than one indicates synergy, while a CI greater than 1 indicates antagonism. An 
example of this is the synergistic inhibition of TNF-α induction by varying combinations 
of nortripyline and prednisolone.21 
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Figure III-3. Loewe definition of synergy. Hypothetical examples of combinations tested 
for synergy using the Loewe (isobolographic) method. In this method, dose-effect curved 
are generated for fixed dose ratios of the two agents. Thus, each combination has two 
IC50s . These IC50's are normalized to the IC50's of the components on their own, and each 
combination is plotted on an x,y coordinate graph based on the amount of compound 
required for 50% effect in the combination divided by the amount of the same agent in 
isolation required for 50%. 
C. The Use of II-2 in Combination with Other Agents that Target ErbB2 Lifetime 
and Activity 
C.1. Rationale for Combination of II-2 and Geldanamycin
Geldanamycin is a naturally occuring antibiotic that binds to the nucleotide pocket 
of the constituitively expressed chaperone Hsp90, causing degradation of Hsp90 client 
proteins.26 In the absence of inhibitor, Hsp90 acts as part of a multi-protein chaperone 
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complex to promote folding of a number of key pro-growth signalling proteins, including 
erbB2,27 into their active forms. Because geldanamycin prevents nucleotide binding and 
the ATP hydrolysis neccesary for Hsp90's chaperone activity, it prevents maturation of 
Hsp90 client proteins and traps them in conformations that are targeted for degredation 
by the cell.28 
A combination of II-2, which inhibits the transcription of erbB2, and Hsp90 was 
therefore hypothesized to reduce cellular levels of erbB2 more effectively that either 
individual component, and to have a greater impact on the survival and proliferation of 
erbB2+ cancer cells (figure III-4). However, geldanamycin has broad activity against the 
range of Hsp90 client proteins and is known to have substantial toxicity in non-
tumorigenic models.29 We hypothesized that the overlapping effects of II-2 and 
geldanamycin on erbB2, but not on other Hsp90 client proteins, would make these 
combinations more selective than either individual agent.  
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Figure III-4. Rationale for synergy between II-2 and geldanamycin. Combinations of II-
2 and geldanamcyin simultaneously target the transcription of erbB2, and reduce the 
lifetime of the mature protein by inhibiting ATPase activity of Hsp90, thereby trapping 
the erbB2-Hsp90 complex in a conformation that promotes erbB2 degradation. 
C.2. Effects of II-2:Geldanamycin Combinations
The hsp90 inhibitor geldanamycin reduces cellular erbB2 levels by preventing the 
hsp90 complex from acting to maintain erbB2 stability and membrane localization. This 
combination exhibited strong synergy as evaluated by an isobologram constructed from 
the dose effect curves of II-2, geldanamycin, and a series of fixed ratio combinations 
(figure II-5). For example, the IC50 of a 5:1 ratio of II-2 to geldanamycin was 
approximately 30-fold lower in II-2 and 17 fold lower in geldanamycin when compared 
to the IC50s of the individual components. Consistent with their modes of action and 
synergistic effect on the growth of SkBr3 cell, use of a combination of II-2 and 
geldanamycin produced a greater reduction in erbB2 levels than use of either agent in 
isolation. 
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Figure III-5. II-2/geldanamycin combinations (I). a) Comparison of the IC50s (in  SkBr3 
cells) of II-2, geldanamycin, and combinations using an isobologram indicate that 
combinations provide a synergistic reduction in the required dose of each compound. The 
combination index, with compounded error from the isobologram, is shown. Error bars 
on the isobologram represent compounded standard error of the IC50s. b) A combination 
of II-2 and geldanamycin is more effective at reducing levels of erbB2 than either agent 
in isolation (p <0.01). Levels of erbB2 were normalized to the total protein concentration 
for each well. Error bars represent the standard deviation of this ratio.
This combination was also synergistic according to the Bliss definition. SkBr3 
cell dosed with II-2, geldanamycin, or a combination of the two were monitored over 
nine days. As illustrated in figure III-6, the combination was more effective than either 
individual agent, or then the expected additive effect of the two compounds over the 
course of the experiment. Concentrations of both compounds below the IC50s were 
chosen to maximize the dynamic range of the assay, and to highlight the ability of 
combination treatment to be effective with drastically reduced doses of the individual 
agents. 
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Figure III-6. II-2/geldanamycin combinations (II). The effects of  II-2 (40 nM), 
Geldanamycin (8 nM) and a combination of the two on ErbB2+ (SkBr3) cells was 
evaluated over 9 days of treatment. Error bars are 1 standard deviation d)  Evaluation of 
individual timepoints indicates indicate a synergistic increase in effect for the 
combination. % effect is calculated by normalizing the % viability to that of the control 
group for each timepoint and subtracting from 100. Predicted additivity is calculated 
according to the multiplicative method of Bliss as described in the supporting 
information. 
In addition to increased activity, it was hypothesized that the use of two agents 
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with broad, but overlapping effects such as II-2 and geldanamycin would provide greater 
selectivity for their shared targets than either agent individually. For these experiments, 
the non-tumorigenic fibroblast cell line IMR90 was used as a negative control. The IC50s 
of each agent and combination for IMR90 cells were divided by the corresponding IC50s 
for SkBr3 cells to produce a selectivity ratio. The selectivity ratios for the combinations, 
normalized to each single agent (II-2 in figure III-7a and geldanamcyin in fig III-7b) 
indicate statistically significant increases in selectivity for all combinations. 
Figure III-7. Selectivity of II-2/geldanamycin combinations (I). The synergy observed 
for II-2:geldanamycin combinations is selective for erbB2+ cells (SkBr3) compared to 
non-tumorigenic cells (IMR90) as indicated by the ratio of the IC50s for each agent (in 
isolation and as part of a combination) in the two cell lines. a) The IC50 ratios for II-2 
IC50's, normalized to the ratio of II-2 as a single agent.  b) The IC50 ratios for 
geldanamycin IC50s, normalized to the IC50 ratio of geldanamycin as a single agent. 
Ratios for II-2 IC50s and geldanamycin IC50s are normalized to those of II-2and 
geldanamycin as single agents. Error bars represent compounded standard error.
To provide an alternative readout that is indicative of the overall selectivity 
increase provided by the combination, we took the ratio of the CI (combination index) in 
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non-tumorigenic (IMR90) cells to the CI in erbB2+ (SkBr3) cells. If the combinations 
were equally synergistic in both IMR90 and SkBr3 cells, this ratio would be 1 as 
indicated by the dotted line in Figure 3c. The fact that the CI ratio is higher than 1 
indicates that the synergy is selective for the target cell population. This can also be seen 
by comparing the isobologram in Figure 3a, which indicates exceptional synergy in 
erbB2+ (SkBr3) cells, to the isobologram in nontumorigenic (IMR90) cells 
(Supplementary Figure S3e) which indicates that the combination is somewhat worse 
than additive in this non-targeted cell population. 
Figure III-8. Selectivity of II-2/geldanamycin combinations (II). a) Comparison of the 
IC50s (in IMR90 cells) of II-2, geldanamycin, and combinations using an isobologram 
indicate that combinations do not provide a synergistic reduction in the required dose of 
each compound. Error bars represent compounded standard error.  The synergy observed 
for II-2:geldanamycin combinations is selective for erbB2+ cells (SkBr3) compared to 
non-tumorigenic cells (IMR90) as indicated by the ratio of combination indices (CI) in 
the two cell lines. Error bars represent compounded standard error.
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C.3. Rationale for II-2:Erlotinib Combinations
Erlotinib is an ATP competitive inhibitor of the receptor tyrosine kinase erbB1 
(EGFR), which is known to form oncogenic heterodimers with erbB2.30 After ligand 
induced dimerization via an erbB1 ligand such as EGF, these two kinases undergo a 
series of auto- and cross- phosphorylation events that lead to the recruitment of signalling 
adapters and activation of the Ras pathway.31 Because of the requirement for dimerization 
and trans-phosphorylation from another erbB protein for erbB2 signaling, we reasoned 
that partial inhibition of both erbB1 function (erlotinib) and erbB2 production (II-2) 
could prove to be an effective way to curb the growth of erbB2 dependent tumors.  
Figure III-9. Rationale for synergy between II-2 and erlotinib. It was hypothesized that 
combinations of II-2 and erlotinib could simultaneously target the transcription of erbB2 
and the ability of erbB1/erbB2 heterodimers to trans-phosphorylate and initiate oncogenic 
signaling. 
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C.4. Effects of II-2:Erlotinib Combinations.
 The combination of II-2 and erlotinib did not appear to exhibit synergy as 
evaluated by either dose reduction or increased activity. An isobologram comparing 
combinations of erlotinib and II-2 to either agent in isolation indicated minimal or no 
reduction in the dose required to achieve 50% effect, beyond that predicted by dose 
equivalent additivity (Figure III-10). This analysis was complicated somewhat by the 
tendency of erlotinib to precipitate out of solution under our experimental conditions at 
concentrations near its IC50, which leads to high errors in the isobologram. To verify this 
lack of synergy, II-2:erlotinib combinations were also tested for their combined effect on 
erbB2 driven SkB3 cells.     
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Figure III-10. II-2/erlotinib combinations (I).Comparison of the IC50s after two days of 
treatment with II-2, erlotinib, and combinations using an isobologram indicates that 
combinations cause an approximately additive reduction in the required dose of each 
compound, but this analysis is complicated by the tendency of erlotinib to precipitate out 
of cell culture media at higher concentrations, which are the concentrations at which 
synergy would be expected. Error bars represent compounded standard error.
No increase in effect was observed by the most effective combination (according 
to the isobologram) of II-2:erlotinib when this was compared to the effects of II-2 or 
erlotinib as single agents. Longer treatment did not lead to an increase in effect over the 
individual agents. The observed lack of synergy, or even of an effect significantly greater 
than that of the individual components of the combination, strongly supports the lack of 
synergy indicated by the isobologram.  
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Figure III-11. II-2/erlotinib combinations (II). a) The effects of  II-2 (10 μM), erlotinib 
(2 μM) and a combination of the two on ErbB2+ (SkBr3) cells was evaluated over 9 days 
of treatment, with no significant increase in effect. b) Evaluation of individual timepoints 
indicates do not indicate a synergistic increase in effect for the combination. % effect is 
calculated by normalizing the % viability to that of the control group for each timepoint 
and subtracting from 100. Predicted additivity is calculated according to the 
multiplicative method of Bliss as described in the supporting information. 
The lack of synergy observed between II-2 and erlotinib may indicate that the two 
interventions are too far removed from each other to effectively combine against the 
tumor cells compensatory mechanisms. As noted above, one of the ways that erbB2 
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driven cancers can escape erbB1 kinase inhibition is to increase the amount of erbB3 
available for dimerization with erbB2.19,20,18 Although RNAi knockdown of erbB2 was 
able to overcome this compensation to a limited degree, first generation small molecule 
transcriptional inhibitors such as II-2 are not direct functional mimics of RNAi, and are 
likely less effective at reducing transcript levels. Furthermore, as SkBr3 cells are thought 
to rely primarily on erbB2/erbB3 dimer formation as opposed to erbB2/erbB1 dimers, 
this may simply indicate that targeting erbB1 is not an especially effective tactic in this 
case – a notion which is supported by comparison of the IC50's of erlotinib and lapatinib, 
a potent inhibitor of both erbB1 and erbB2. 
C. 5. Rationale for Combination of II-2 and Lapatinib. 
Like erlotinib, lapatinib is an ATP competitive kinase inhibitor that interferes with 
a necessary autophosphorylation event that occurs in between dimerization and 
recruitment of signaling adapters.32 Unlike erlotinib, lapatinib is a highly effective 
inhibitor of both erbB1 and erbB2.33,34 We therefore hypothesized that reduction in erbB2 
levels (II-2) and inhibition of erbB2 kinase activity (lapatinib) would reduce the overall 
amount of phosphorylated (active) erbB2 and have a synergistic impact on the viability of 
cells dependent on erbB2 driven signaling. (figure III-12)
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Figure III-12. Rationale for synergy between II-2 and lapatinib. Combinations of II-2 
and erlotinib simultaneously target the transcription of erbB2 and the ability of 
heterodimers that include erbB2 to trans-phosphorylate and initiate oncogenic signaling.
C.6. Effects of II-2:Lapatinib Combinations
The effects of this combination were assessed using an ELISA assay to measure 
levels of erbB2 and phospho-erbB2 in response to treatment (Figure 2b). As expected, II-
2 had  moderate  effects  on  both  erbB2  and  phospho-erbB2  levels.  However  the  II-
2:lapatinib combination was significantly (p < 0.05) more effective at reducing the total 
amount  of  active  (phosphorylated)  erbB2  than  equivalent  amounts  of  either  II-2 or 
lapatinib.
Fixed ratio combinations of II-2 and lapatinib provided a significant reduction in 
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the doses required for 50% effect on erbB2+ cell viability. As shown in the isobologram 
in figure III-13 this reduction is greater than that would be predicted from additive dose 
equivalence.  A 500:1  combination  of  II-2:lapatinib  was  the  most  synergistic  of  the 
combinations employed, and was chosen for followup studies evaluating the possibility 
of a synergistic increase in effect. 
The ability of a combination of this 500:1 combination of II-2 and lapatinib at sub 
IC50 doses to affect the viability of SkBr3 (erbB2+) tumor cells was compared to the 
effects of II-2 and lapatinib in isolation. A dramatic increase in effect was observed for 
the combination when compared with either individual agent, and this combination effect 
also exceeded the predicted additive effects of the two individual components, as shown 
in figure III-13.
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Figure III-13. II-2/lapatinib combinations (I). a) After 1 day, a combination of II-2 and 
lapatinib is more effective at reducing levels of active (phosphorylated) erbB2 than either 
agent in isolation (p <0.05). Levels of erbB2 and p-erbB2 were normalized to the total 
protein concentration for each well. Error bars represent the standard deviation of this 
ratio. b) Comparison of the IC50s after two days of treatment with  II-2, lapatinib, and 
combinations  using  an  isobologram indicates  that  combinations  provide  a  synergistic 
reduction  in  the  required  dose  of  each  compound.  Error  bars  represent  compounded 
standard error. 
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Figure III-14. II-2/lapatinib combinations (II). a) The effects of  II-2 (5 μM), lapatinib 
(10 nM) and a combination of the two on ErbB2+ (SkBr3) cells was evaluated over 9 
days  of  treatment,  with  a  drastic  increase  in  effect  observed for  the  combination.  b) 
Evaluation  of  individual  timepoints  indicates  a  synergistic  increase  in  effect  for  the 
combination. % effect is calculated by normalizing the % viability to that of the control 
group for each timepoint  and subtracting from 100.  Predicted additivity is  calculated 
according  to  the  multiplicative  method  of  Bliss  as  described  in  the  supporting 
information.  All  experiments  were  carried  out  in  triplicate  and  error  bars  represent 
standard deviation unless otherwise indicated.  
As with  the  II-2:geldanamycin  combinations,  the  effects  of  II-2,  laptinib  and 
various combinations were assessed in IMR-90 cells to expore the possibility of increased 
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selectivity from combination use. Selectivity compared to II-2 as a single agent is clearly 
increased by use of  II-2:lapatinib combinations.  However,  lapatinib by itself  was not 
toxic to IMR-90 cells at the concentrations tested, thus precluding the construction of an 
isobologram for the effects of these combinations in IMR-90 cells, or the evaluation of 
selectivity  when  compared  to  both  agents.  The  increased  selectivity  observed  in 
comparison to  II-2 remains a useful piece of data, as it indicates that these compounds 
are not synergistically toxic and that combinations allow greater effect to be achieved 
before the dose limiting toxicity of the more toxic component becomes prohibitive. 
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Figure III-15. Dose effect curves for  II-2/lapatinib combinations. a) Dose-effect curves 
used to generate isobolograms for  II-2:lapatinib concentrations, displayed as a function 
of  lapatinib  concentration.  500:1  II-2:lapatinib  is  from a  seperate  plate  in  which  the 
lapatinib IC50 was 48 ± 17 nM. b) Dose-effect curves used to generate isobolograms for 
II-2:lapatinib concentrations. 500:1 II-2:lapatinib is from a seperate plate in which the II-
2 IC50 was 13.7 ± 1.0 μM. c) Dose-effect curves used to generate isobolograms for II-
2:lapatinib  concentrations  in  IMR90  cells.  d)  Dose-effect  curves  used  to  generate 
isobolograms for II-2:lapatinib concentrations in IMR90 cells, displayed as a function of 
lapatinib  concentration.  All  experiments  were  carried  out  in  triplicate  and  error  bars 
represent standard deviation unless otherwise indicated.   
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D. Conclusions
Combinations  of  II-2  and  either  the  Hsp90  inhibitor  geldanamycin  or  the 
erbB1/erbB2 kinase inhibitor lapatinib were shown to be synergistically more effective at 
curbing  the  proliferation  of  erbB2  driven  SkBr3  cells  than  any  of  the  individual 
components, or the predicted additive effects of these components. These effects lead to 
greater  selectivity  for  combinations,  particularly  in  the  case  of  II-2:geldanamycin 
combinations, as judged by their relative effects on SkBr3 cells (erbB2+) compared to 
IMR-90 cells (non-tumorigenic).  
By  using  a  combination  that  simultaneously  curbs  expression  of  the  genetic 
driving force behind a diseased state while also targeting related cellular processes we 
achieve a synergistic increase in effect that is specific to the target cell population. Taken 
as a whole, these data demonstrate a generalizable strategy for overcoming the activity 
and  selectivity  limitations  of  transcriptional  inhibitors.  This  approach  promises  to 
improve the utility of transcriptional inhibitors as both biochemical tools, and potential 
therapeutics. By demonstrating the potential of this approach, these results also suggest 
that this  strategy could be successfully applied to other systems that are regulated by 
complex networks of protein-protein interactions.      
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E. Supporting Information.
E.1. Materials
Isoxazolidine i1 was prepared as described in chapter 2 Lapatinib ditosylate and 
erlotinib were purchased from AK scientific, and geldanamycin was a generous gift from 
Dr. Brian Blagg. The identity and purity of all compounds were verified by NMR 
analysis and HPLC. Antibodies were purchased from Santa Cruz Biotechnology. 
Absorbance data was collected on a Tecan GENios Pro. 
E.2. Calculation of synergy
IC50s were calculated in Graphpad Prism v 5.0. All other calculations were 
performed in excel. Isobolograms were generated by computing dose fractions directly 
from the IC50s. Dose fraction is defined as the dose of one component in a combination 
required to exert a given effect (usually IC50, as in this case) divided by the dose of that 
component in isolation required to exert the same effect. Thus each combination reported 
has two dose fraction measurements (eg. dose fraction i1 and dose fraction lapatinib) that 
define the combinations x/y coordinates on the isobologram. 
Dose fraction of A for combination AB = IC50(A in AB) / IC50(A in isolation)
Dose fraction of B for combination AB = IC50(B in AB) / IC50(B in isolation)
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The sum of these x/y coordinates are the combination index. By definition, the CI for 
either agent in isolation is 1. For the null hypothesis (in which both agents act as though 
they are equivalent doses of the same agent) the CI will be 1. For combinations where the 
CI < 1, synergy is present.  
CI (combination index) = dose fraction A + dose fraction B.
Bliss additivity for a given combination was calculated by multiplying the fractional 
effect of the two components, according to the formula given below for combination AB 
whose components have effects eA and eB (which are expressed as fractional effects 
between 0 and 1) in isolation.
Predicted effect of AB = (eA+eB) - (eA*eB)  
E.3. Mammalian Cell Culture
SkBr3 and IMR90 cells were purchase from ATCC and cultured in RPMI 1640 
(SkBr3) or DMEM (IMR90) with 10% FBS and no antibiotics. 
For the experiments used to generate dose-effect curves for the isobolograms and 
selectivity experiments, cells were plated at 3000 cells per well in 96 well plates. After 
adhering overnight, media was changed to 2.5% FBS and compound (as a solution in 
DMSO) was added. New media and compound were added for each additional day of 
treatment (2 days in the case of lapatinib and 3 days in the case of geldanamycin). The 
day after the final treatment, cell viability was measured using WST-1 reagent (Roche) in 
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accordance with the manufacturer's instructions. 
For the 9 day cell growth assays cells were plated at 15000 cells per well in 24 well plates 
(one for each timepoint to minimize potential for contamination). Doses at or below the 
IC50's from the above experiments were chosen to maximize the dynamic range of the 
assay. These experiments were otherwise run in the same way as those done in 96 well 
plates. 
E.4. ErbB2 and p-erbB2 ELISA:
ELISA assays were performed based on those published elsewhere.35 SkBr3 cells 
were plated in 10% FBS at 15000 cells per well in 24 well plates. After adhering 
overnight, media was changed to 2.5% FBS and compound was added. After 24 hours, 
media was removed carefully and cells were fixed and permeabilized with cold (-20º C) 
methanol. The cells were then washed twice with TBST, blocked for 2 hours at room 
temperature with superblock (TBST solution from Pierce), incubated with the primary 
antibody overnight at 4º C (as a 1:500 solution in superblock). Cells were then washed 
twice more with TBST and incubate with secondary antibody for 2 hours at room 
temperature (as a 1:1000 solution in superblock). After being washed 3 times with TBST, 
Slow TMB (Pierce) was added to measure antibody levels in accordance with the 
manufacturer's instructions and the absorbance at 370 nm was measured. The cells were 
washed 3 more times with TBST and total protein levels were measured at 560 nm using 
BCA reagent (Pierce). ErbB2 and p-erbB2 levels were normalized to total protein 
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concentration by calculating (A370-A370blank)/(A560-A560 blank), where the A370 
blank was from TMB treated cells not treated with a primary antibody, and the A560 
blank was BCA reagent in wells that did not have cells plated in them. The resulting 
ratios were then normalized to cells treated with DMSO.
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Chapter IV
Design and Implementation of a Peer-Led Discussion Module for Teaching Research 
Ethics to Incoming Graduate Students.a
A. Chapter Overview
The need for explicit discussion of research ethics and professionalism outside of 
the student-adviser relationship has been well established.1,2,3,4,5,6 As researchers who are 
responsible for generating and publishing original research, graduate students are a key 
audience for these discussions. However, at the time this module was designed, there was 
no formal medium for these issues to be discussed within the department. In collaboration 
with a fellow graduate student – Amy Danowitz – I designed and taught a short module to 
address this deficiency. The goal of this module was to provide incoming students with 
the tools and awareness to deal productively with the ethical issues that they are likely to 
encounter in their roles as researchers and graduate students. We used small and large 
group discussions and case studies designed to be both believable in scale and relevant to 
the concerns of incoming graduate students. Based on student responses to the module, 
and feedback from the chemical community, this module was an effective tool for 
a Parts of this chapter appear in Danowitz, A. M.; Taylor, C. E. Integrating a Peer-
Taught Module on Practical Research Ethics into the Graduate Student Orientation 
Curriculum. Journal of Chemical Education 2011, 88, 1090–1093.
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increasing student's ability to formulate and identify constructive solutions to ethical 
problems, and a valuable contribution to the literature on teaching research ethics. 
B. Background
B.1. Definitions of Scientific Misconduct
Science, as a cumulative and often cooperative undertaking, relies on a reasonable 
amount of trust between different researchers. In the absence of such trust, the exchange 
of information and the dissemination of results that are essential to the present research 
paradigm become suspect and ultimately useless. Accordingly, funding agencies actively 
discourage research misconduct. The Office of Research Integrity, which is also 
responsible for investigating alleged misconduct and administering penalties to offenders, 
defines research misconduct in terms of falsification, fabrication, and plagiarism.7 
Research misconduct means fabrication, falsification, or plagiarism in proposing, 
performing, or reviewing research, or in reporting research results. (a) Fabrication 
is making up data or results and recording or reporting them. (b) Falsification is 
manipulating research materials, equipment, or processes, or changing or omitting 
data or results such that the research is not accurately represented in the research 
record. (c)  Plagiarism is the appropriation of another person's ideas, processes, 
results, or words without giving appropriate credit. (d) Research misconduct does 
not include honest error or differences of opinion. 
Although these definitions are generally used when misconduct is discussed, they are not 
comprehensive. They are not generally interpreted to include activities such as sabotage, 
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the misrepresentation of experimental protocols, or the use of research designs that are 
known to be inadequate or inappropriate.  
B.2. Occurrence of Scientific Misconduct
There are numerous well-document and highly publicized cases of research 
misconduct. These include extensive forgeries such as those of Hendick Schon at Bell 
labs,8 in which Dr. Schon was found to have fabricated the data used in a series of papers 
published in several journals, including both Nature and Science. A more recent example 
of misconduct comes from a research lab at Columbia University,9,10 which involved 
some 21 counts of, fabrication and falsification by a graduate student and led to the 
retraction of 6 papers. Another recent example, albeit one that does not fit the technical 
definition of misconduct, took place at the University of Michigan.11 In this case, it was 
determined that a post-doctoral researcher had been sabotaging a graduate students 
research for a period of several months, with total damages estimated at approximately 
$70,000. There is an emerging consensus in the literature that these cases represent only 
the 'tip of the iceberg' and that there are many instances that go unreported.12,13,14
The prevalence of research misconduct has been evaluated by administering 
anonymous surveys, in which researchers are asked about their own conduct and that of 
their colleagues. Although there is variation in the estimated frequency of misconduct 
depending on the definitions and methods used, the data from surveys consistently 
indicate a surprisingly high rate of questionable or inappropriate conduct. In an analysis 
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of approximately 3,000 NIH funded researchers, Martinson et al.14 determined that 
although only 0.3% of their respondents admitted to 'Falsifying or cooking research data,' 
15% admitted to 'dropping observations or data points from analyses based on a gut 
feeling that they were incorrect,' and 13.5% admitted to using inadequate or inappropriate 
research designs. A meta analysis of the literature on misconduct12 concludes that the 
falsification rates reported by Martinson are probably artificially low, in part because the 
language used asks specifically about falsification and fabrication (which researchers are 
reluctant to admit to) rather than particular behaviors that fall under these categories. The 
overall results from the meta-analysis indicate that approximately 2% of respondents 
admit to having falsified or fabricated at least one piece of data themselves, while 15% 
had knowledge of a coworker who has done so. Frequency of other questionable practices 
(such as using inappropriate research designs, or reporting intentionally incomplete 
methodological data) were approximately 30% for self-admission, and 70% for observed 
behavior of coworkers. At this point, the causes of the discrepancy between the self-
reported rates of misconduct and the rates of known or observed misconduct are largely 
speculative. In addition to the obvious explanation – that researchers are reluctant to 
admit to misconduct even under anonymous conditions – it is possible that the rates of 
known or observed misconduct include events that are suspected but unproven, or 
multiple reportings of single events or persons known to many researchers. Despite this 
caveat, data such at these indicate that researchers often act in ways that damage the 
implicit trust and openness that is part of the ethos of modern science.   
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A Format for Ethical Decision Making
Adapted from a handout written by Professor Michael Davis, for the Teaching 
Research Ethics conference in 2009. Used with permission. 
1) Determine the problem. 
The initial problem may be an explicitly ethical one (e.g. 'I think this data was 
fabricated') or it may not be (e.g. 'I am going to miss a research deadline'). 
2) Determine/check facts.
As much as possible, try to separate objectively verifiable facts from suspicions 
or rumors. In many cases, the issue may change or disappear upon careful 
consideration. 
3) Consider limitations and objectives. 
There will probably be many goals involved in a situation – maintaining personal 
integrity, advancing your career, making a favorable impression with your 
advisor or other faculty members, your relationship with your peers, etc. 
4) Develop a list of 2-3 options. 
Be specific about courses of action – who would you talk to, how would you 
discuss the issues, etc.
5) Test Options. The following are good examples of tests that are not necessarily 
dependent on specific ethical theories. 
Harm test – does this option do less harm than any of the other alternatives?
Publicity test – would I want my choice of this option known throughout the 
department?
Defensibility test – could I defend this choice in front of faculty members or 
other authorities? If so, what would I say? 
Reversibility test – would I still think this was the best option if I were one of the 
people adversely affected by it.
6) Choose an option based on steps 1-5. 
7) Consider what you can do to make it less likely that this issue will come up 
again.  
Box IV-1. A Format for ethical decision making. A handout given to students to provide 
common basis for discussions of ethics and problem solving strategies.
B.3. Addressing the Causes of Scientific Misconduct
There is not a single explanation for the root cause of scientific misconduct. One 
view13 holds that the vast majority of science is conducted in accordance with ethical 
norms, but that a few 'bad apples' are responsible for gross violations of these norms and 
that these cases receive a disproportionate amount of publicity. Other views13 hold that 
misconduct is driven by flaws in the research culture of either particular institutions, or 
that of science as a whole. It is plausible that these explanations are all true to one degree 
or another – that there are (rarely) unscrupulous researchers who will commit fraud out of 
hand, but that much of the driving force for misconduct and lesser offenses comes from 
an inability on the part of researchers to cope with the pressures placed on them by their 
environment. This view of misconduct as a failed coping strategy is implicit in the 
instutional and cultural explanations for misconduct. It also indicates that education on 
the responsible conduct of research should address 'survival skills' in addition to simply 
defining various sorts of misconduct. 
This expanded view of research ethics education closely parallels recent findings 
by the National Academy of Science,15 which offered a general critique of many current 
research ethics courses that amount to 'another box for institutions to check.'  In 
particular, the council's findings emphasized the need for interactivity, the use of case 
studies or an equivalently engaging method, and that ethics training will only be effective 
to the extent that researchers can simultaneously be both ethical and successful. 
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C. Pedagogical Rationale for Module Design  
C.1. Module Goals and Approach
In line with the recommendations made by the National Academy of Science15 as 
well as the ideas presented by Coppola3 and Rytting and Schowen2 that the drive for 
personal success and desire to comply with external pressures can outweigh moral 
concerns, we designed the module around the idea that most students do not start out with 
the intention of committing morally dubious acts; rather, they might do so in response to 
the pressures that they face as graduate students.  This line of reasoning indicates that 
ethical decision-making and the ability to navigate the conflicts and hazards of graduate 
school are closely intertwined.
In designing the content of this module, we had three major goals.  First, we 
wanted to provide students with examples of potential moral dilemmas that they were 
likely to face as first and second year graduate students. As noted by Kovac,5
"It is essential that students be able to relate to both the context and the characters 
[of a given situation].  If the people and the scenario are too distant, students will 
tend to see the situation in simplistic right-or-wrong terms."  
In order to provide the students with examples they could relate to, we constructed a 
series of case studies based on problems that arose among our peer group during their 
first and second years.  
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We also designed these studies to serve as a vehicle for students to practice their 
ethical reasoning skills.  In particular,  we wanted them to base their  interpretations on 
facts rather than suspicions or rumors, identify stakeholders and propose solutions that 
would benefit (or at least minimize harm to) these parties, and to evaluate the immediate 
and long term effects of potential actions. These criteria were given in detail in a handout 
titled  ‘A  Format  for  Ethical  Decision  Making,’  which  was  adapted  from  material 
presented at the Teaching Researching Ethics conference (Box IV-1).  Another purpose of 
these discussions was to illustrate that it is often possible to mitigate external pressures 
and  thus  alleviate  the  temptation  to  commit  ethically  dubious  acts.  In  the  course  of 
working through a case study, students were asked to commit to an appropriate course of 
action prior to discussion. We did this in order to give them practice in making such a 
commitment in a relatively safe and low-stakes setting.  
Second, we aimed to give students practice in not only identifying potential 
dilemmas, but also in addressing their concerns about ambiguous situations in a 
professional and respectful manner. This was emphasized because of the possibility that, 
even if students lead exemplary research careers, there may be questions about the work 
of a collaborator or coworker. The way in which these questions are pursued is of great 
importance, as can be seen by examples such as the unresolved case in Baltimore,16 
which including raids by the Secret Service and in which the original finds of scientific 
misconduct by the Office of Research Integrity were later overturned by a Health and 
Human Services appeals panel. Given the highly collaborative nature of science, and the 
possible outcome of a poorly handled false accusation of misconduct on the part of a 
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coworker or collaborator, the ability to voice concerns about potential misconduct in a 
calm and appropriate manner is essential.
The idea of sharing concerns and discussing potential conflicts brings us to our 
final goal: giving students a detailed over-view of the personnel and resources that can be 
involved in conflict resolution (for example the Graduate Committee and the Ombud’s 
office) and the types of issues that are appropriate for each resource.  It has been our 
experience  that  graduate  students  are  often  unaware  of  resources  other  than  their 
coworkers and adviser.  By providing students with this list and helping them to decide 
whom they should approach with a given problem, we placed potential solutions to moral 
dilemmas within their grasp.
In  order  to  meet  these  goals,  we  developed  six  case  studies  and  a  data 
interpretation  exercise  that  we used as  vehicles  to  discuss  issues  such as  authorship, 
plagiarism, resolution of intra-lab conflict, and data integrity from the perspective of a 
first or second year graduate student. 
C.2. Rationale for Peer-Leadership
Senior  graduate  students  are  uniquely  suited  to  lead  discussions  about  the 
challenges and ethical dilemmas that face incoming graduate students at their institution. 
Advanced  graduate  students  work  in  the  same  departmental  environment  that  the 
incoming students will, and often have recent first or second hand experiences that they 
can draw on in designing and discussing case studies. Senior students only have to look 
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back a year or two in order to empathize with the concerns of new students and are in a 
unique position to address the current concerns in a rapidly changing research climate.  It 
must be noted, however, that senior graduate students lack a firsthand faculty perspective 
on these issues. For this reason, we found it extremely useful to consult with faculty 
members in determining discussion points and potential solutions for each case study.
Additionally,  the  fact  that  graduate  students  are  leading  discussions  on  ethics 
indicates to incoming graduate students that the subject matter is important to their peer 
group, and by extension, should be important to them. Furthermore, we think it likely that 
students are more candid around other students than they would be if faculty members 
were leading the sessions. This is particularly true in the case of new graduate students 
who may worry about making a good impression on a potential adviser or committee 
member. 
D. Module Layout and Implementation
We implemented this  module in two, two-hour blocks over  the course of two 
days. The sequence began with us giving a brief presentation on the resources that are 
available  to  graduate  students  in  dealing  with  conflicts,  particularly  those  that  could 
either lead to misconduct on their part or stem from the misconduct of other researchers. 
Students participated in a brainstorming session that addressed different sorts of conflicts 
that can arise in graduate school. The peer leaders (the authors) then guided a large group 
discussion  about  the  most  appropriate  venues  for  resolving  these  problems.  This 
135
discussion  included  potential  steps  for  escalation  of  unresolved  problems,  and  of 
alternative courses of action for cases where the usual resources, such as the student's 
adviser, were not appropriate.       
Most of the module was based on case studies that focused on dilemmas that 
students might face as first or second year graduate students.  Students discussed cases in 
small groups (4-6 students) with the discussion leaders moving from group to group in 
order to facilitate discussion.  The entire group then discussed the case, with students 
volunteering  solutions  or  feedback  on  other  students'  solutions.   At  this  stage,  the 
discussion leaders acted as moderators and guided the group towards a general consensus 
on  the  best  courses  of  action  for  each situation.   In  both the  small  and large  group 
discussions, students were encouraged to consider the long term consequences of each 
proposed action  and to  think  about  other  stakeholders  who may be affected  by their 
actions. Peer leaders and students also discussed the differences between professional and 
unprofessional ways of handling conflicts. 
 The module ended with an 'off the record' question and answer session, in which 
students could ask the discussion leaders questions about graduate school, or broach any 
unaddressed concerns that they had. Student had the opportunity to ask questions during a 
period in which an advising faculty member was present, or after the faculty member left. 
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E. Module Content 
E.1. Example Data Interpretation Exercise. 
 To give students concrete examples of how data analysis can lead to questions that 
affect the integrity of the researcher, we used an exercise and group discussion that dealt 
with interpreting and presenting ambiguous data to illustrate the ethical dimensions of 
this process. After a brief presentation on what qualifies as fabrication, falsification and 
plagiarism,  students  were  presented  with  examples  of  data  such  as  synthetic  yields 
obtained when testing the efficacy of two different ligands (Box IV-2).  The students were 
also given a list of potential conclusions that could be drawn from the data.  They then 
discussed circumstances under which a given conclusion would or would not be valid. In 
the latter case, students also considered whether inappropriate conclusions represented 
poor science or misconduct, and discussed the factors that determine this distinction.
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E.2. Example Case Studies
The case study in Box IV-3 presents students with a plausible complication in 
what is commonly considered one of the most stressful experiences of the early years of 
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Box IV-2. Sample data interpretation exercise. Data interpretation exercise based on the 
evaluation of two ligands for an organometallic reaction. Students are asking to evaluate 
the scientific and ethical reasonability of several potential conclusions, and to propose 
alternatives. 
graduate school. This case study is designed to present students with a situation in which 
there is an obvious short term gain from an inappropriate but seemingly minor action. 
The discussion of this case study dealt primarily with evaluating the potential long term 
complications for ethically dubious actions, such as knowingly glossing over problems 
with one's research (as in a or b), and with finding alternative solutions that helped the 
student highlight their research efforts and deliver a compelling candidacy exam in spite 
of these difficulties. 
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Many of  the  student  responses  addressed  issues  from the  ‘Format  for  Ethical 
Decision Making’ handout that we had previously discussed with them.  Several students 
brought  up the potential  effects  of their  actions on their  adviser  or collaborators (i.e. 
additional  stakeholders).  Other  responses  included  assessment  of  potential  long-term 
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Case Study - “Key Result”
You are a second year student, and you have been working in your thesis lab for 
several months. You are working on the document that you will submit to your 
candidacy committee. Your thesis research is quite ambitious and your advisor 
has warned you that your committee members are likely to be skeptical. 
Nevertheless, you are confidant that it will work and by hard work and luck, 
have acquired an early result from one of your key experiments that 
demonstrates proof of concept for your work. While you are writing the paper, a 
fact comes to light that casts doubt on the veracity of your results (see below). 
There is not time to repeat the experiment before the deadline for your candidacy 
document. 
In which of these situations (and with what qualifiers) is it permissible to include 
the questionable experimental results in your document and presentation. 
Situation A) 
You realize that you did not perform a necessary control to rule out a likely 
confounding factor in your key experiment.    
Situation B) 
A serious technical problem is brought to your attention (e.g. the instrument you 
collected data on was incorrectly calibrated, etc).   
Situation C) 
You find a paper with an experiment very similar to yours, but which has a 
significantly different result, and from which the authors draw conclusions which 
indicate that your idea should not work.
Box IV-3. Case Study - “Key Result.”A case study in which the student faces a potential 
crises before candidacy and must determine how best to solve the problem in a way that 
meets both academic and ethical standards. 
effects, for example, that feigning ignorance of the needed control in situation A could set 
the student up for further acts of fabrication or falsification if they are faced with the 
invalidation of their ‘results’ later on. 
In addition to recognizing the ethical issues embedded in the case study, students 
proposed solutions that allowed them to meet the demands of graduate school without 
committing misconduct or setting themselves up to do so in the future. For example, in 
situation B, the possibility was raised that students may be able to postpone candidacy 
until the systematic error has been fixed, rather than present suspect data. For situation A, 
students discussed ways to present the limitations of the data (i.e. “absent this control we 
see…”) that might allow them to discuss their data without misrepresenting their results. 
These responses indicate that students are seeing beyond the simplistic binary dilemma of 
committing a morally dubious act or failing to meet imposed standards.
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For  another  case  study  (Box  IV-4),  students  discussed  the  possibility  of 
misconduct on the part of a coworker.  These sorts of problems may arise when multiple 
scientists contribute to a project. It is therefore important for students to think about how 
to determine if misconduct has occurred.  Students should also practice professional and 
courteous ways of broaching these types of concerns with other scientists.
For  this  exercise,  students  proposed  specific  details  that  would  lead  them to 
believe that either (a) misconduct had been committed by the previous student or (b) the 
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Box 2: Case Study - “Continuing a Project”
You have inherited a project from a 6th year graduate student who has left the lab. 
 The student's work was published as a communication, and your thesis research 
will be a series of followup studies based on their initial results. Your advisor 
suggests that you repeat some of their experiments to “test your hands” at the 
technique they had been using.  After running their experiments as written up in 
the experimental section of their communication for several weeks, you are 
unable to reproduce their data. You go through their notebooks and contact them 
via email in order to try and determine what is going wrong with your 
experiments.
Propose two situations/results from your actions (emailing and looking through 
notebooks) which would cause you be concerned about misconduct, and two 
situations which would not. 
(For example, if the student emails back that there is a minor technical issue that 
she forgot to record, and once you this into account, your experimental results are 
consistent with those in the paper, misconduct is unlikely). 
For one of the situations in which misconduct may be an issue, propose both a 
reasonable course of action (who would you talk to, what would you say) and a 
less reasonable course of action for dealing with the situation.  
Box IV-4. Case Study - “Continuing a Project.”A case study in which students propose 
potential situations that would meet the criteria for either a case in which suspicion of 
misconduct is warranted, or which can likely be ascribed to honest mistakes by a 
collaborating researcher. 
previous student had not committed misconduct.  This gave students the opportunity to 
become creatively engaged with the material, and opened up the discussion to a wider 
variety of circumstances and issues than if they were given a single, completely defined 
case study. In one instance, a student proposed a detailed situation based directly on their 
previous research experience, and asked the group for their interpretation. This illustrated 
both  the  plausibility  of  these  sorts  of  situations  and  the  importance  of  the  resulting 
discussion. 
The  second  portion  of  this  case  study  centered  on  appropriate  responses  to 
situations where a student believed misconduct may have occurred. Specifically, students 
proposed professional ways of dealing with this  conflict  and noted the importance of 
presenting the facts of the case, rather than their suspicions or opinions about the former 
student.  During  these  discussions,  students  again  brought  up  the  possible  affects  on 
stakeholders in this situation and suggested courses of action would entail the least harm 
to those involved. For example, some students initially found it reasonable to first take 
these concerns to a party outside the lab for a second opinion (in particular, a former 
adviser or other trusted faculty member). Upon further discussion, they realized that this 
option has potential consequences for both themselves and their current adviser.  They 
also pointed out that this solution fails the reversibility test, as they would be displeased 
with the adviser or former student broaching concerns about their work to one of their 
peers rather than to them. 
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F. Response by Students and the Larger Chemical Community
Responses  to  the  module  from both  the  students  who  have  taken  it,  and  the 
broader community have been positive. During both the years it was offered, students 
indicated that they found the case studies and resulting discussions to be both useful and 
eye-opening. The only substantive critique of the module offered by students was that too 
much  time  was  being  given  to  the  individual  case  studies.  In  reponse  to  this,  we 
incorporated additional details into each case rather than holding them back for the large 
group discussion. The time for small group discussions was reduced, which allowed us to 
implement the data interpretation exercise described above. 
After the first year in which the module was presented, the ACS invited us to 
deliver a  presentation about our experiences. This presentation was very well received, 
with several members of the audience commenting that they thought we should write this 
up for publication. The resulting publication was accepted with enthusiastic reviews and 
minimal revisions in the Journal of Chemical Education. 
G. Conclusions
The purpose of this module was to introduce incoming graduate students to the 
methods and tools that they can use to navigate the ethical hazards of graduate research. 
Students  practiced  these  skills  by  working  through  a  number  of  exercises  based  on 
scenarios that they may face in the next couple of years. Students were also advised on 
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potential resources that they can call on to help resolve ethical issues that arise in the 
course of their research.  
We used the nature of the responses given by the new graduate students to asses 
the  effectiveness  of  the  module.  These  responses  indicate  that  students  were  able 
assimilate the lessons and identify the larger moral dimensions of the situations presented 
in the case studies.  They were able to propose solutions that allowed them to maintain 
both  their  ethical  and  professional  integrity,  without  failing  to  meet  the  demands  of 
graduate  school.  The  students’ ability  to  articulate  the  issues  in  these  scenarios  and 
propose reasonable solutions to them indicates that they are beginning to appreciate the 
nuances of ethical decision making. Student responses also show an understanding of the 
need to consider the long term effects of decisions on both themselves and others. 
Recently,  Rackham  has  mandated  that  all  departments,  including  Chemistry, 
implement credited courses on the responsible conduct of research and that these course 
be taught by faculty. Although the implementation of this course will make the module 
redundant,  the rationale  behind the module's  construction,  and much of  the materials 
generated for it are being adapted to this new course. Additionally, one of the graduate 
students  who  designed  and  implemented  this  module  –  Amy  Danowitze  –  will  be 
teaching the department's responsible conduct of research course in collaboration with a 
full time member of the faculty. 
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H. Course Materials
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Case Study: Authorship
As part of your rotation, you run an experiment to identify an unknown protein 
by MS/MS. You perform the technical aspects of the experiment, under the 
supervision of your rotation mentor. Your mentor also helps you work up and 
analyze the data. Based on these results, the protein is tentatively identified. After 
your rotation ends, you hear that the group is writing up a paper in which the 
identification of this protein is used as supporting evidence for a proposed 
regulatory mechanism. 
Under what circumstances is your omission from the authorship list reasonable? 
Under what circumstances is it a problem? If it is a problem, how could you go 
about addressing this?
One of the key questions is how significant of a contribution you made to the 
experiments resulting in the initial identification of this protein. Propose factors 
that (1) would clearly indicate that you made a significant contribution to the 
project, (2) would clearly indicate that you did not make a significant 
contribution, or (3) fall somewhere in between. 
Box IV-5. A case study in which students evaluate the different criteria for authorship on 
a paper, and propose ways of addressing situations in which they believe correct 
attribution has not been made.  
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Case Study: Safety Issue
You are rotating in the lab you wanted to join. Your rotation project is going well, 
and you get along well with most of your labmates. However, the post-doc who 
works next to you often leaves flasks of the chemicals she is working with 
uncapped and on the bench. You have politely asked her to deal with them in an 
appropriate manner, but she has told you not to worry about it – none of them are 
especially toxic, and besides part of your job as a chemist is putting up with 
unpleasant smells. 
Propose reasonable and unreasonable courses of action for each of the following 
conditions:
1) The chemical is not particularly toxic (eg. Acetone, Ethyl Acetate). 
2) The chemical is something potentially toxic or carcinogenic (eg. Hexanes, 
Dichloromethane).
3) The chemical readily decomposes to Hydrogen Cyanide (Volatile and Lethal). 
4) Changes to any of the above, if the lab's advisor is out of town for an extended 
period of time.
Box IV-6. A case study in which students propose different ways of dealing with a 
potential safety hazard caused by one of their senior coworker. A key part of the resulting 
discussion is resolving the situation in a manner which makes the research environment 
safe for the student, but which does not alienate coworkers or the adviser. 
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Case Study: Rotation Project
You are several weeks into a rotation in the research lab that you would like to 
join. Although the lab's research focus interests you, the senior graduate student 
you are working with is having you run reactions for his methodology project 
according to a protocol that he has already developed and using substrates that he 
has already decided upon.  
This lab only will only be accepting a single new student at the end of the year, 
and has already had three rotators. You do not have much direct interaction with 
the lab's advisor, and other lab members have told you that whether or not you are 
selected to join the lab will depend almost entirely on the presentation you give at 
the end of your rotation. This presentation is given to the entire group, including 
the advisor, and you will be expected to present and discuss the work you have 
completed during your rotation. You are concerned that your lack of creative 
input in your project will negatively affect the quality of your presentation and 
your chances at being accepted into this lab. 
Are there circumstances under which this would not be a problem (describe 
them)? How would you go about determining whether or not this is the case?
Assuming that it turns out to be a problem, propose both a reasonable and 
unreasonable solution. 
Box IV-7. A case study in which students evaluate a potential intra-lab conflict, in which 
their rotation mentor may or may not be assigning them projects that will adversely affect 
their academic goals. A key part of the resulting discussion revolves around the highly 
variable nature of these sorts of practices between labs, and the fact that what may be a 
problem in one lab could be standard practice in another.  
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Case Study: Inspiration
You are finishing up a rotation in the lab you intend to join, and have an 
upcoming meeting with your future advisor in which the two of you will discuss 
potential thesis projects.  All during your rotation, you had been thinking about a 
project based on a future direction presented by a graduating PhD student in the 
lab you worked in as an undergraduate.  You think this project fits in nicely with 
what your grad lab is doing, builds on your current skills and interests, and will 
be exciting enough to send out as a JACS or perhaps a PNAS paper if it works. 
You are sure that your new advisor would be as excited about this idea as you are. 
What practical and ethical concerns should you have about proposing this 
project? 
For the following situations, propose both a reasonable and unreasonable course 
of action. 
1) Your undergraduate advisor is retiring and you know they are no longer 
carrying out research.
2) You know the project is intended as an REU project for the next summer. 
3) The original idea for this project came from either an experimental result of 
yours (as an undergraduate) or a conversation between you and your 
undergraduate advisor and/or the graduate student who mentored you.  
Box IV-8. A case study in which students evaluate the potential for plagiarism of a 
research idea from an old lab. In particular, students are encouraged to come up with 
ways in which they can (given appropriate permission) use the idea, without violating 
academic and ethical standards. 
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Box IV-9. A data interpretation exercise in which students are asked to evaluate and 
amend potential conclusions reached using one or both of the above graphs.
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Box IV-10. A data interpretation exercise in which students are asked to discuss, evaluate 
and amend conclusions based on a series of Western Blot assays. For this particular 
exercise, some knowledge of the principles and technical considerations of Western Blot 
analysis is highly beneficial. 
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Chapter V 
Conclusions and Future Directions
A. Inhibition of ErbB2(Her2) Expression with Small Molecule Transcription Factor 
Mimics
A.1.  Conclusions
We set out to determine if a scaffold that can act as synthetic transcriptional 
activators would could be tailored to inhibit the activity of a particular activation domain. 
At the outset it was unclear whether or not the promiscuous nature of natural activator-
coactivator interactions would pose serious problems for inhibition. The data suggest that 
isoxazolidine II-2 is a much improved mimic of the transcriptional activation domain of 
ESX relative to the generic TAD mimic II-1, validating our strategy for using an artificial 
TAD as a scaffold for the design of transcriptional inhibitors.  Treatment of ErbB2+ 
cancer cells with isoxazolidine II-2 reduces erbB2 mRNA and protein levels, indicating 
that the molecule effectively interferes with the ability of ESX to activate transcription of 
erbB2. This molecule is also effective at attenuating the growth and viability of erbB2 
overexpressing cancer cells, which is consistent with the expected effects of an erbB2 
transcriptional inhibitor. However, II-2, suffers from the same limitations to its potency 
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and selectivity as other small molecule transcriptional inhibitors. 
A.2. Rationale for the Use of Helical Peptidomimetics in Order to Identify 
New Ligands for the Transcriptional Machinery
Because amphipathic transcriptional activation domains are believed to have 
largely helical character when they interact with their coactivator targets,1 the use of 
polymeric scaffolds designed to mimic helices may enable the rapid identification of 
effective inhibitors of transcription. Several examples of this have emerged recently and 
are discussed below. Such structures could also be used to develop artificial activation 
domains. If native TADs take on a helical interaction when recruiting coactivators, 
artificial constrained helices may prove to be extremely potent activation domains.   
154
Figure V-1. Rationale for isoxazolidine based inhibitors. Isoxazolidines which are 
designed to mimic key functionality on the ESX TAD are effective at countering 
erbB2 overexpression.  
A.2a. Peptidic Scaffolds
Recent results have shown that L-peptides which have been covalently 
constrained into short helices are effective inhibitors of transcription. In one example, a 
constrained helix was used to block the dimerization of transcription factors required to 
initiate transcription at the NOTCH promoter.2 In the other, a short constrained helix was 
designed based on a region of the activation domain of HIF-1α. This peptide was shown 
to bond to the CH1 domain of CBP, and to inhibit HIF-1α driven gene expression in cell 
culture.3  
The potential uses of peptidic ligands for the transcriptional machinery are 
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Figure V-2. Helical inhibitor of HIF-1α mediated transcription.Constrained helical 
peptides such as the one shown here have been used successfully as transcriptional 
inhibitors. X = pentenoic acid. The covalent tether is the result of an alkene 
metathesis between the terminal alkene of pentenoic acid, and an allyl group attach to 
the backbone nitrogen of the aspartic acid. The dotted lines and dashed circle labed 
'coactivators' represent steps in the recruitment process that are uncharacterized, but 
likely given the prevailing model.
twofold. First, such molecules could be used as activators or inhibitors in their own right. 
In principle, the ability to rapidly synthesize peptide based molecules that have high 
affinity and selectivity for a particular target (or that are selective mimics of a particular 
activation domain) could prove to be a valuable tool for evaluating the consequences of 
particular inhibition strategies. 
On the other hand, such peptidomimetics could also be used to inform the design 
of small molecules. Constrained helices in particular provide a well-defined interaction 
surface that can be perturbed in predictable ways by substituting in natural or unnatural 
amino acids. Once a short but effective peptide sequence is identified, and the most 
important contacts are known, computational analysis could be used to identify scaffolds 
that would place functionality in the appropriate places. This could enable structure-based 
design, even in circumstances where very little was known about the coactivator. 
A.2b. Synthetic Scaffolds
An alternative approach would be the use of synthetic polymers as helical mimics. 
Work by the Hamilton lab identified Terphenyls as approximate mimics of the i, i+3, i+4 
positions of an α-helix (Figure V-3).4 Subsequent studies have focused primarily on 
altering the scaffold to reduce its hydrophobicity5 and expand the range of amino acid 
substitution patterns that can be mimicked.6 In order to apply these scaffolds to 
transcription, it would likely be necessary to identify a system in which the positions 
mimicked by the terphenyl corresponded with important amino acids in the native TAD, 
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but as these positions fall on one face of the helix that is unlikely to pose a major 
problem. The primary drawbacks of this method are the size and lipophilicity of the 
resulting synthetic polymers, and the fact that they are imperfect and less constrained 
mimics of helical arrangements, so drawing using them to inform the design of smaller 
synthetic molecules would be less straightforward than for constrained helical peptides. 
B. A Multi-Pronged Approach to Targeting Oncogenic Transcription
B.1. Conclusions
In spite of their considerable therapeutic potential, the development of highly 
157
Figure V-3. Non-biomolecule helical mimics. a) The original terphenyl design 
mimicked the i, i+3 and i+7 positions on a helix. b) A newer indane is designed to 
mimic the i, i+3, and i+4 positions. 
potent and selective transcriptional inhibitors has proven elusive. Biological factors such 
as the promiscuous and low affinity nature of activator-coactivator interactions, and the 
shared nature of coactivators make these issues difficult to solve by traditional means. 
However, the use of transcriptional inhibitors such as II-2 in combination with other 
agents  provides a generalizable strategy for overcoming the activity and selectivity 
limitations of transcriptional inhibitors. By using a combination that simultaneously curbs 
expression of the genetic driving force behind a diseased state while also targeting related 
cellular processes we achieve a synergistic increase in effect that is specific to the target 
cell population.  This approach promises to improve the utility of transcriptional 
inhibitors as both biochemical tools, and potential therapeutics. By demonstrating the 
potential of this strategy, these results also suggest that it could be successfully applied to 
other systems that are regulated by complex networks of protein-protein interactions. 
B.2. Application of Synergy to p65 Regulated Transcription 
NF-κβ subunit p65 plays a central role in the canonical  NF-κβ pathway,7 where is 
forms a dimer with the DNA binding subunit p50. The two activation domains of p65 
then recruit the machinery needed to initiate transcription. The role of  NF-κβ in 
processes such as inflammation and oncogenesis makes this a system with direct 
applications to human health.8 In addition, unlike ESX mediated transcription of erbB2, 
p65 is part of a well-characterized regulatory network that acts to control p65 release and 
nuclear transport. Inhibitors have been developed that target several of these events. For 
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example, several molecules have been identified that inhibit the kinase activity of IKKα 
and/or IKKβ, which (together with NEMO) form the complex responsible for 
phosphorylating and triggering the degradation of IKβα, which holds p65 and p50 in an 
inactive state in the cytoplasm.9 It is likely that the use of inhibitors that target processes 
upstream of the transcription factor in question (as in this case) will be an effective 
alternative to synergy with inhibitors that target downstream processes (as were used in 
the case of erbB2 expression). Furthermore, this provides a highly complimentary 
approach, as it will provide selectivity for the activity of a particular activator, while the 
downstream synergy provides selectivity for one particular target of an activator. It is 
possible that this broader selectivity will be useful in cases like  NF-κβ that regulate 
several genetic programs which have interrelated cellular effects.
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Figure V-4. Upstream vs. downstream synergy. The use of secondary agents that 
target processes upstream of transcription would increase selectivity for programs 
initiated by a particular activator (p65 in this case). Combinations of a transcriptional 
inhibitor with secondary agents that target downstream processes would increase 
selectivity for a particular subset of the processes driven by a particular activator. In 
this case, selectivity for metastasis would be increased relative to the effects on 
proliferation of inflammation. 
B.3. The Use of Synergy to Alter the Selectivity of a Transcriptional Inhibitor 
An additional application of synergy is the potentual use of two different 
secondary agents to switch the selectivity of a transcriptional inhibitor from one pathway 
to another. For example, both p65 and HIF-1α are thought to depend on contact with the 
CH1 domain of CBP in order to initiate transcription.10,11 It is therefore likely that 
inhibitors which bind the CH1 domain of CBP will affect both of these pathways, in 
addition to the activity of any other transcriptional activator proteins that rely on contact 
with the CH1 domain. 
However, if the use of secondary agents that act on processes up- or down- stream 
of a specific activator produces a selective and synergistic effect on that activator's 
activity, this can be expanded to produce selectivity for either activator. In this case, the 
combination of a CH1 targeting transcriptional inhibitor and an IKK inhibitor would be 
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Figure V-5. Rationale for CH1 binding peptides as inhibitors of p65 mediated 
transcription.CH1 binding peptides can be used to inhibit the interaction between p65 
and CBP that is necessary for p65 iniated recruitment of the transcriptional 
machinery. The dotted lines and dashed circle labed 'coactivators' represent steps in 
the recruitment process that are uncharacterized, but likely given the prevailing 
model.
selective for p65 driven transcription, while the use of the same CH1 targeting 
transcriptional inhibitor and  an inhibitor of HIF-1α DNA binding would be selective for 
HIF-1α driven transcription. 
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Figure V-6. Complementary approaches to synergy. By using different secondary 
agents, synergistic combination could allow CH1 binding peptides to act selectively 
on either the canonical NF-κβ pathway (p65 driven) or HIF-1α driven transcription.  
C.  Design and Implementation of a Peer-Led Discussion Module for Teaching 
Research Ethics to Incoming Graduate Students
C.1. Conclusions
The purpose of this module was to introduce incoming graduate students to the 
methods and tools that they can use to navigate the ethical hazards of graduate research. 
Students practiced these skills by working through a number of exercises based on 
scenarios that they may face in the next couple of years. Students were also advised on 
potential resources that they can call on to help resolve ethical issues that arise in the 
course of their research. The students’ ability to articulate the issues in these scenarios 
and propose reasonable solutions to them indicates that they are beginning to appreciate 
the nuances of ethical decision making. Student responses also show an understanding of 
the need to consider the long term effects of decisions on both themselves and others.   
C.2. Future Opportunities for the Discussion of Research and Data 
Interpretation. 
Recently, Rackham has mandated that all departments, including Chemistry, 
implement credited courses on the responsible conduct of research and that these course 
be taught by faculty. Although the implementation of this course will make the module 
redundant, the rationale behind the module's construction, and much of the materials 
generated for it are being adapted to this new course. Additionally, one of the graduate 
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students who designed and implemented this module – Amy Danowitz – will be teaching 
the department's responsible conduct of research course in collaboration with a full time 
member of the faculty. The materials in this module could also be expanded and adapted 
for use as in research group meetings. In this way, it would provide a vehicle for 
individual advisers to discuss and establish group standards for conflict resolution, safety, 
and data interpretation. 
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Appendix I
The Design and Evaluation of d-Peptide Inhibitors of p65 Mediated Transcription
A. Overview
The misregulation of transcription is associated with a wide variety of human 
diseases, such as cancer.1,2 In spite of this, generalizable methods to modulate 
transcription remain elusive. An archetypal example of a transcription factor that drives 
pathological gene expression is the NF-κB subunit p65, which plays a key role in 
processes such as inflammation and oncogenesis.3,4 P65 is known to make contacts with 
the KIX and CH1 domains of the coactivator CBP,5 and the TA1 and TA2 activation 
domains of p65 are likely responsible for mediating other protein-protein contacts 
necessary for the initiation of transcription.6,7 D-peptide mimics of the TA1 
transcriptional activation domain of p65, and a d-peptide version of known CH1 and KIX 
binding peptides were tested for their ability to inhibit the transcriptional activity of p65. 
Although results indicate that the CH1 binding peptide (A1-7) may be effective at 
reducing p65 activity in response to TNFα stimulation, further investigation is needed to 
confirm the mechanism of this effect, and the development of more effective inhibitors 
would be highly beneficial. 
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B. Background
B.1. NF-kB subunit P65
The NF-kB family of proteins includes the transcriptional activators RelA (p65), 
RelB, and C-rel, in addition to the proteins p50 and p52.8 A heterodimer of p65 and p50 is 
the active transcription factor commonly referred to as NF-kB, and the primary driver of 
NF-kB activity under the canonical NF-kB signaling cascade.9 
The TAD of p65 is generally divided into two regions TA1 (521-551) and TA2 
(428-521).6 The transcriptional activity of both Gal4-TA1 and Gal4-TA2 fusion proteins 
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Figure A1-1. Rationale for inhibition of p65 mediated transcription. It is possible that 
p65 mediated transcription could be inhibited by peptidomimetics that are designed to 
bind to known activator binding regions of CBP – thus inhibiting the interaction between 
p65 and CBP, or by peptidomimetics designed to mimic the activation domain of p65, 
thereby blocking probable interactions between p65 and components of the mediator 
complex. 
suggests that these domains are able to function individually as transcriptional activation 
domains. However, either TA1 or TA2 is sufficient to squelch activity of RelA(286-551) 
in COS cells.10 The activity of the TA1 domain appears to be dependent on the presence 
of two phenylalanines (F534 and F542).11 Repeats of a sequence containing one of these 
regions of the TA1 domain were seen to activate transcription, and a putatively 'TA1-like 
region' has been identified in TA2.10 On the whole, results from the literature suggest the 
existence of 2 or more potentially redundant domains that are both capable of squelching 
each other when not fused to a DNA binding domain. This in turn suggests that a peptide 
mimic of any one of these regions may be effective at reducing the activity of DNA 
bound p65. 
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Figure A1-2. Major domains of p65. 
B.2. CBP
Creb-Binding Protein (CBP) and its paralog p300 act as coactivators for hundreds 
of transcriptional activation proteins.12,13 Although the details of their role in faciliting 
transcription appears to be complex and heavily context dependent, they may act to 
localize Histone Acetyl Transferases to open up the chromatin structure near the 
promotor, or to recruit general transcription factors such as TFIIB and TFIIB to aid in 
formation of the pre-initiation complex at the promoter. 14,15 CBP and p300 have several 
domains which are known to bind to overlapping sets of transcriptional activators. In 
particular, the KIX and CH1 domains of CBP are known to interact with a variety of 
transcriptional activation domains, including p65.5,12  
B.3. P65-CBP interactions
It has been established that transcription via p65 is mediated by the homologous 
coactivators CBP and p300.16,17 The C-terminus of p65 contains 2 activation domains 
(TA1 and TA2) either of which can activate transcription when fused to a DNA binding 
domain.6 Early indications of the interaction between CBP/p300 and p65 came from the 
Nabel lab,17 where p300 was found to coprecipitate with p65-CDK complexes, and to 
enhance the activation of p65 by the cell cycle regulatory protein p21. Work from Collins 
and co-workers16 supports that both CBP and p300 can potentiate p65-driven 
transcription of a reporter gene. The results of these experiments also indicated 
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interactions between p65 286-551 (which contains both the TA1 and TA2 domains) and 
the N-terminal regions of both CBP and p300. The results of a series of experiments by 
Zhong and coworkers5 indicate the presence of an interaction between the KIX domain of 
CBP and p65, which is dependent on p65 S276 phosphorylation, and a phosphorylation-
independent interaction between the C terminal region (TA1 and TA2) of p65 and the N 
terminal region (1-450) of CBP, which contains the CH1 domain. 
Taken together, these experiments indicate that CBP and/or p300, particularly the 
N terminal domains such as KIX and CH1, play a key role in mediating p65 dependent 
transcription. This makes sense, given that both the KIX and CH1 domains are well-
validated targets for many other transcription factors.12,14 However, the functional 
significance of these potential interactions is not clear. 
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Figure A1-3. Putative interactions between p65 and the coactivator CBP. The interaction 
between the Rel Homology Domain (RHD) of p65 and the KIX domain of CBP is shown 
in blue. The interaction between the activation domains of p65 (possibly either TA1, 
TA2, or a combination) and the CH1 domain is shown in red.  
C. Design of d-peptide inihibitors of p65 transcriptional activity
Enantiomeric  d-peptides  were  used  to  increase  the  proteolytic  stability  of  the 
peptides,  thereby making  degradation  by cellular  proteolysis  less  of  a  factor  in  their 
activity.  Peptides were tagged with a fluorescein isothiocyante (FITC) label at the N-
terminus  to  aid  in  quantification,  and  to  allow  cellular  uptake  to  be  assessed  by 
fluoresence  microscopy.  An  8-Amino-3,6-Dioxaoctanoic  Acid  ('MiniPeg')  linker  was 
used to attach the fluorescein label to the N-terminus of the d-peptide, in order to prevent 
the  label  from  interfering  with  the  peptides  ability  to  interact  with  CBP  or  other 
coactivators. Although some of the peptides, such as the CH1 binding d-peptide were 
expected to be cell permeable, most were given a C-terminal hexaarginine tag to increase 
cell uptake. 
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Figure A1-4. General schematic of the d-peptide inhibitors designed to curb p65 activity. 
LinkerFluorescein d-Peptide
D-peptide mimics of the TA1 domain focused on the activator sequence DFSALL. 
This six-residue sequence has been shown to activate transcription when repeated and 
fused to a DNA binding domain, and is thought to be one of two necessary portions of the 
TA1 domain.11 As shown in Table IV-1, d-peptides incorporating additional positively 
charged amino acids (A1-1 to A1-4) were synthesized to test alternatives to hexaarginine 
cell permeability tags. 
The CH1 binding d-peptide (A1-7) was based on a 'hydrogen bond surrogate' 
developed by the Arora lab,18 in which a hydrocarbon bridge was used to mimic the 
hydrogen bonding pattern of an alpha-helix and hold the peptide in a helical 
conformation. The KIX binding d-peptide (A1-6) was based on earlier work in the Mapp 
lab, in which peptidic ligands for the KIX domain of CBP were evaluated by fluorescence 
polarization.19 
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Table A1-1. D-peptides designed to inhibit p65 mediated transcription. 
D. Activity of d-Peptide Inhibitors of p65 Mediated Transcription 
D.1. Activity Against TNFα Induced p65 Driven Gene Expression 
The initial readout for peptide activity was their effect of the induction of 
NFKBIA (Iκβα) by TNFα treatment. Iκβα is a well-known target of p65 activity in this 
context, forming part of a negative regulatory loop that then serves to reduce p65 activity 
back to basal levels.20,21,22 The CH1 binding peptide A1-7 and potentially the TA1 mimic 
with the hexaarginine tag (A1-3) appear to reduce p65 mediated activation of Iκβα. Other 
peptides, including the TA1 mimic with a single arginine (A1-1), and the KIX binding 
peptide (A1-6) did not appear to have an effect. The hexarginine tag by itself (A1-5) 
appears to cause an increase in Iκβα induction, possibly as a side effect of the toxicity 
attributed to highly cationic molecules.23,24 Although this effect is likely attentuated in 
longer peptides which contain the hexaarginine sequence, it is still a potential 
confounding factor. This complication highlights the importance of finding an acceptable 
balance between cell permeability and excess positive charge. 
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Figure A1-5. Results from initial screen of d-peptides. Initial results of quantitative PCR 
(qPCR) experiments used to evaluate the effects of d-peptides on tnf induced, p-65 
mediated expression of Iκβα. All data represent the median of experiments from a single 
biological sample run in triplicate, normalized to matching tnf negative controls. 
A more thorough test of the CH1 binding peptide A1-7 and the A1-3 indicates that 
the former is likely to have a significant impact on p65 activity, while the latter may not. 
A1-7 was also tested for its ability to interfere with transcription of a second p65 target,  
the oncogene ICAM-1. Although these results lack statistical significance, it does suggest 
an effect by A1-7. 
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Figure A1-6. Results from followup evaluation of A1-3 and A1-7. Results of qPCR 
experiments used to evaluate the effects of d-peptides on tnf induced, p-65 mediated 
expression of Iκβα. All data represent the median of experiments from 3 biological 
samples, each run in triplicate, normalized to matching tnf negative controls. 
P <0.05
D.2. Cellular Uptake of d-Peptides
In order to deconvolute the effects of potentially limited cellular uptake on the 
activity of the peptides, we employed fluorescence microscopy to analyze the ability of 
the peptides to enter cells. Results indicate uptake of both A1-7 and A1-3. However, 
nuclear permeability appears to be limited at best. This may be a limiting factor on the 
activity of these peptides, though the effectiveness of the structurally similar HBS 
peptides18 suggests that these peptides might have effects in spite of limited nuclear 
permeability. An additional TA1 mimic A1-4, using a nominal nuclear localization 
sequence (RRRK) was synthesized by Paul Bruno, but a significant increase in nuclear 
permeability was not seen. More effective strategies to induce nuclear uptake of these 
peptides may increase their activity substantially. 
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D.3.  Effects  on  the  Activity  of  Gal4-p65  Mediated  Transcription  of  a 
Luciferase Reporter
In an effort to validate potential mechanism, and to assess their effects under more 
controlled settings, peptides A1-3, A1-4, and A1-7 were tested for their ability to curb the 
activity of a Gal4-p65 construct. Results indicate that none of the peptides was effective 
at concentrations up to 50 µM. This is not suprising in the case of peptides such as A1-3, 
which were not observed to be effective against p65 driven transcription of Iκβα. The 
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Figure A1-7. Results of fluorescent microscopy experiments. These were carried out to 
determine cellular permeability of promising d-peptide inhibitors of p65 activity. Results 
shown are for compounds at 50 μM, 24 hours after addition of compound. Hoechst stain 
was used to visualize nuclei and the fluorescein tag was used to visualize peptides.  
failure of  A1-7 to inhibit  Gal4-p65 activity suggests that  CBP may not  be neccesary 
under the assay conditions, perhaps due to the reduced chromatinization of the reporter 
gene environment.  Additionally, as the construct utilized for these assays included both 
the TA1 and TA2 activation domains of  p65, it  may be more useful  to  test  peptides 
against the individual domains initially, and then optimize promising leads to affect the 
activity of a construct containing both domains. 
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Figure A1-8. Results of luciferase reporter assays. These were designed to evaluate the 
ability of d-peptides to inhibit the activity of the TA1 and TA2 domains of p65.   
E. Conclusions
A series  of  proteolytically  resistant  d-peptides  were  designed  to  inhibit  p65 
mediated activation. A peptide based on a known CH1 binding motif (A1-7) appears to 
interfere  with  p65  mediated  transcripion  at  low  to  mid  micromolar  concentrations. 
Cellular uptake of this  peptide is reasonable,  though it  may suffer from poor nuclear 
localization. Peptides designed to mimic the TA1 domain (A1-1 through A1-4) did not 
appear  to  be  effective  in  either  reducing  p65  mediated  response  to  TNFα,  or  to 
attenuating the ability of a Gal4-p65 construct to activate transcription of a reporter gene.
Confirmation  of  the  proposed  mechanism of  action  for  the  A1-7  would  lend 
additional results more weight. A direct measurement of the peptide's ability to interfere 
with  the  interaction  between P65 and the  CH1 domain  would  be  particularly useful. 
Potential methods for this include binding curves based on the fluorescence polarization 
of a tagged peptide based on the p65 TA1 or TA2 domains interacting with the CH1 
domain  of  CBP in  the  presence  or  absence  of  inhibitor.  Surface  plasmon resonance, 
luciferase  complemenation,  or  isothermal  calorimetry provide  alternative  methods for 
examining this interaction. 
One of the primary future directions for this project include the identification and 
application of peptides that inhibit p65 mediated transcription. If the activity of A1-7 can 
be reliably reproduced, combinations of this peptide and other agents that target up- or 
down-  stream points  on  the  canonical  p65 signaling  pathway may prove  synergistic. 
Furthermore,  such  combinations  have  the  potential  to  offer  a  form  of  switchable 
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selectivity, in which a CH1 binding peptide and an agent that targets the HIF-1α pathway 
have very different phenotypic selectivity and effects that the same CH1 binding peptide 
and an agent that targets the canonical p65 pathway. Additionally, the identification of 
more effect nuclear localization elements would be extremely useful to the development 
of this and other peptidomimetics that act on nuclear processes.  
F. Supplementary Information
F.1. Materials
Peptides were synthesized using standard solid phase synthesis techniques from 
Fmoc protected d-amino acids purchased from Peptides International. The identity and 
purity of peptides was determined by mass spectrometry and HPLC analysis. Peptides 
were quantitated using by taking their A280 in a 1:1 solution of water:methanol. Peptides 
were then concentrated to white powder using a lyophilizer. Taqman probes for RT-qPCR 
were purchased from Applied Biosystems. 
F.2. Cell Culture and qPCR assays
 HEK293T cells were grown in DMEM with 10% Fetal Bovine Serum without 
antibiotics. Cells were plated at approximately 50,000 cells per well in 24 well plates. 
After adhering overnight, media was replaced and cells were dosed with d-peptides in 
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DMSO (1% final concentration). After 24 hours, TNFα (10ng/mL final concentration) 
was added to half the wells to induce p65 release and activity. After 4 hours, RNA was 
harvested  using  an  RNAeasy  kit  from  Qiagen,  according  to  the  manufacturer's 
instructions. RNA was quantified by UV/Vis analysis,  and 1 ug of each sample were 
subjected  to  a  reverse  transcription  reaction  in  accordance  with  the  manufacturer's 
instructions  (Applied Biosystems).  qPCR reactions  were  then  carried out  in  triplicate 
from single samples of cDNA using TaqMan probes. Data was analysed using the ΔΔCT 
method, comparing TNFα treated cells to untreated cells and using Ribosomal Subunit p0 
as an internal control for each cDNA sample.
F.3. Luciferase Assays
HEK293T Cells were plated at 3,000 cells per well in white 96 well plates. After 
adhering  overnight,  cells  were  transfected  for  4  hours  (optimem  and  lipofectamine 
according to the manufacturer's instructions) with 250 ng/mL of a plasmid coding for a 
fusion of Gal4(1-100) and p65(286-551), as well as 500 ng/mL of a plasmid containing 5 
Gal4 binding sites upstream of a luciferase reporter (PG5Luc) and 40 ng/mL of a plasmid 
that constituitively expresses Renilla (PRLSV40). After transfection, media was changed 
back to DMEM+10% FBS and cells were dosed with d-peptides in DMSO (1% final 
concentration). After 24 hours, Luciferase and Renilla activity were measured using the 
Dual-Glo assay kit (Promega) in accordance with the manufacturer's instructions. 
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F.4. Fluorescence Microscopy 
HEK293T cells  were  plated  in  glass  microscopy  slides  at  a  concentration  of 
approximately 400,000 cells per slide in 1 mL of media and allowed to adhere overnight. 
Cells were then dosed with d-peptides in DMSO (1% final concentration) for 24 hours. 
Hoechst stain (0.5  μL in an additional mL of media for a final concentration of 0.25 
μL/mL) was added and incubated for 15 minutes. After this, the cells were rinsed very 
carefully with cold, sterile PBS, and then 2 mL DMEM + 10% FBS but without phenol 
red was added. Cells were then observed using filters for Hoechst stain and fluorescein. 
Images  were  worked  up  and  combined  in  Photoshop  CS.  This  protocol  produced 
somewhat faint nuclear staining, and the concentration of Hoechst stain should probably 
be doubled in future experiments.  
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Appendix II
Applications of a Novel Synthesis of Substituted Alleneamides via a [3,3] 
Sigmatropic Rearrangementa
A. Overview
The identification of new scaffolds for small molecules that interact with 
transcriptional activators or coactivators is an area of ongoing research. Because of the 
putatively helical nature of amphipathic activation domains,2 and the success of 
isoxazolidines such as II-13 and II-2,4 we sought out new methods for the rapid and facile 
generation of small molecules that have a dense, radial display of functionality. 
Alleneamides serve as a precursor to many such scaffolds, however, the generation of 
asymmetric and densely substituted alleneamides has proven difficult. 
Previous research in the Mapp lab identified a rearrangement of allylic 
phosphorimidates to phosphoramidates that could be used to construct allylic amines.5,6 
Building on these discoveries, we developed a route to alleneamides via the [3,3] 
rearrangement of phosphorimidates. The starting material for this reaction is synthesized 
by a one-step functionalization of propargylic alcohols, which in turn are available either 
a Parts of this chapter are reproduced in Danowitz, A. M.; Taylor, C. E.; Shrikian, T. 
M.; Mapp, A. K. Palladium-Catalyzed [3, 3]-Rearrangement for the Facile 
Synthesis of Allenamides. Organic Letters 2010, 12, 2574–2577.
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commercially or through well known reactions. This method is suitable for the generation 
of protected mono-, di-, or tri- substituted alleneamides, and the use of chiral propargylic 
alcohols allows the stereoselective synthesis of asymmetric alleneamides. Finally, the 
alleneamides generated using this method are unusually stable, and undergo reactions 
similar to those of allenes rather than electron rich alleneamides, thus providing a novel 
building block in the construction of complex and densely functionalized molecules. 
B. Background
B.1. The Role of Alleneamides in the Discovery of New Scaffolds for the 
Design of Small Molecules Ligands of Transcriptional Activator Proteins 
Small molecules that regulate transcription by interacting with transcriptional 
coactivator proteins have great promise as both biochemical tools and therapeutics. 
However, a very limited number of such molecules have been discovered.7,2 The 
identification of additional scaffolds that could be used to design new ligands for the 
transcriptional machinery would facilitate development of new and potentially more 
effective ligands. The utility of allenes and alleneamides in the rapid and modular 
synthesis of complex small molecules makes them attractive building blocks for the 
contruction of new scaffolds. 
B.2. Reactivity of Allenes and Alleneamides 
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Allenes themselves can act as either nucleophiles or electrophiles, with the 
reactivity and selectivity being heavily dependent on the nature of the substituents.8 
Alleneamides are generally more nucleophilic than allenes, owing to the electron 
donating character of the nitrogen (Figure A2-1). Alleneamides are known substrates for 
a variety of reactions leading to densley functionalized cyclic molecules such as densley 
functionalized pyrans,9 oxazolidonyl substituted heterocycles,10 and dihydrofurans.11 A 
facile route for the preparation of alleneamides would therefore lend itself to rapid 
preparation of libraries of these compounds. 
B.3. Previously existing routes to alleneamides 
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Figure A2-1. Applications for alleneamides. Alleneamide precursors can be used to 
generate a variety of densely functionalized heterocycles. 
Known methods for the preparation of alleneamides have two general limitations: 
length, and control of stereochemistry. The iterative synthesis of allenamides is 
commonly performed in the literature, but the installation of each sustituent requires a 
seperate reaction under strongly basic conditions, and any stereocontrol must come from 
a chiral auxilliary.8 Alternative routes exist that use either the copper catalyzed coupling 
of allenyl halides to amides,12 or the [2,3]-rearrangement of propargylic sulfides.13 
However, in both cases the selective preparation of asymmetric alleneamides requires the 
use of chiral starting materials (allenyl halides or propargylic sulfides) that are difficult to 
prepare. 
C. [3,3] Rearrangement of Phosphorimidates
C.1. Substrate Preparation and Optimization of Reaction Conditions
The phosporimidate was generated as described in Figure A2-3 from a propargylic 
alcohol, a chlorophosphite, and then Staudinger reduction with an azide. Optimization of 
reaction conditions included screening solvents, concentrations, temperature and 
phosphorous ligands. The conditions which reliably produced the best yield were the use 
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Figure A2-2. Iterative construction of allenamides. One of the existing ways to 
synthesize functionalized allenamides is the iterative route shown above. After base 
induced isomerization from a propargylic amide to an allenamide, sequential rounds of 
deprotonation and treatment with electrophile are used to functionalize the alleneamide. 
of either Dicholormethane or Toluene at room temperature as the solvent, at a substrate 
concentration of 10 μM, and using diethyl phosphorochloridate as the chlorophosphite. In 
particular, low substrate concentration was found to be necessary, indicating the potential 
for unwanted intermolecular reactions. 
C.2. Evaluation of Reaction Scope
These condititions were subsequently used to test the scope of the reaction, as 
shown in Table A2-1. The reaction can be used to synthesize alleneamides which have 
bulky substitutents at either the 1 or 3 position, but does not provide access to 3,3-
disubstituted alleneamides, as the corresponding phosphorimidates fail to form. Both 
branched and straight-chain alkane substituents form the desired alleneamides in 
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Figure A2-3. General scheme for alleneamide synthesis. The general route developed to 
synthesize alleneamides is shown above. In brief, a propargylic alcohol is transformed to 
the corresponding phosphorimidate via treatment with a chlorophosphite, followed by 
reduction with a protected azide. This phosphormidate undergoes rearrangement to the 
corresponding alleneamide (a phosphoramidate) in the presence of a palladium catalyst. 
moderate to good yields. 
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Table A2-1. Scope of the rearrangement. 
C.3. Synthesis of Asymmetric Alleneamides
Synthesis of the enantiomers A2-6 and A2-8 was achieved with good 
enantioselectivity (92% in both cases). In the case of the bulkier alleneamide A2-14, 
enantioselectivity was reduced (80% ee). This was unusual, given that a rearrangement 
would be expected to proceed in a highly stereoselective manner. In order the determine 
whether the problem was reduced enantioselectivity of the rearrangement, or subsequent 
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A Conditions as described above. See section F for additional details. B Isolated yields. C ee 
of commercially available starting alcohol found to be <95% in each case. D ee 
determined by chiral HPLC.
racemization of the product, the alleneamide A2-14 was re-subjected to the reaction 
conditions as shown in A2-4. The time dependent reduction in enantioselectivity indicates 
that the alleneamide undergoes racemization under the reaction conditions. This 
racemization was likely more pronounced with alleneamide A2-14 than A2-6 or A2-8, 
because of the longer reaction times needed for its formation.
D.  Applications of Alleneamides in Organic Synthesis
The usual reactivity pattern for alleneamides or allenamines is dominated by the 
electron donating character of the nitrogen. This is in contrast to allenes, where steric 
considerations tend to control reactivity. Initial attempts to use alleneamides such as A2-2 
in known reactions for alleneamides or allenamines8 resulted in decomposition, or the 
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Figure A2-4. Racemization of A2-14. This is indicated by both the apparant time 
dependence of racemization, and by the fact that resubjecting A2-14 to the reaction 
conditions causes the loss of enantiopurity. A Yield recovered based on the amount 
resubjected to the reaction conditions. 
a
recovery of starting material. Based on the presence of two electron withdrawing groups 
on the nitrogen, and the observed benchtop stability of these alleneamides, which 
contrasts with the rapid degradation that has been observed for allenamines and some 
other allenamides, we hypothesized that electron donation into the allenic system by the 
nitrogen was significantly reduced. Given this, we tested the utility of these diprotected 
alleneamides in reactions generally used for allenes. In addition to traditional reactions 
such as Diels-Alder or 2+2 cycloadditions,14 we also wanted to determine if the allene 
could be used for organometallic reactions with reasonable selectivity for the less 
hindered  olefin. Based on conditions described in the literature,15 we were able to effect a 
palladium catalyzed tandem acylation/borylation to form A2-26, which is primed for 
further reactions. 
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Figure A2-6. Applications of A2-1. The relatively electron-neutral character of the di-
protected alleneamides allows them to be used in reaction previously unknown for 
alleneamides, such the one used to generate A2-26. 
E. Conclusions 
A novel synthesis of di-protected alleneamides from phosphorimidates was 
developed. This method provides several advantages over existing routes to alleneamides, 
including the facile synthesis of substituted alleneamides and the unusual reactivity of the 
products. By incorporating an additional protecting, the resulting alleneamides are more 
stable than those generated by other routes, and their reactivity is complementary, with 
reactions occuring at the distal olefin rather than the proximal olefin, as is common with 
other alleneamides. 
Future lines of investigation include extending the functional group tolerance of 
this method, and developing a palladium free variation that avoids racemization of the 
product under the reaction conditions. Although attempts at thermal catalysis have been 
unsuccessful, there is evidence in the literature that gold catalysis may be a useful 
alternative to palladium in this case. Finally, the success of this project provides a tool for 
the rapid synthesis of complex molecules that may act as ligands or inhibitors for parts of 
the transcriptional machinery.          
F. Supplementary Information.
Unless otherwise noted, starting materials were obtained from commercial 
suppliers and used without further purification.  DCM, Et2O, and toluene were dried by 
passage though activated alumina columns and degassed by stirring under a dry nitrogen 
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atmosphere.  Purification by flash chromatography was carried out with E. Merck Silica 
Gel 60 (230-400 mesh) according to the procedure of Still, Kahn, and Mitra. All reactions 
involving air- or moisture-sensitive compounds were performed under a nitrogen 
atmosphere.  Cbz azide was prepared according to literature procedure.  
3-Phenylprop-2-yn-1-ol, 3-(4-chlorophenyl)prop-2-yn-1-ol, 3-(3-
methoxyphenyl)prop-2-yn-1-ol, and 3-(4-methoxyphenyl)prop-2-yn-1-ol  were prepared 
according to literature procedures.  1H and 13C NMR spectra were recorded in CDCl3 at 
400 or 500 MHz and 125 MHz.  IR spectra were measured as thin films on NaCl plates.  
General procedure for allenamide preparation via rearrangement: 
N
P
O
Cbz
HO TEA
1)
2) CbzN3
O
P NCbz PdCl2(CH3CN)2
OEt
EtO OEt
OEt
Cl-P(OEt)2
R
R1
R
R1
R
R1
To Et2O (10 mL) cooled in an ice/H2O bath was added the propargylic alcohol 
(1.3 mmol, 1.6 eq) and Et3N (1.0 mmol, 1.3 eq), followed by dropwise addition of diethyl 
chlorophosphite (1.0 mmol, 1.3 eq).  The solution was allowed to stir for 20 min and the 
precipitated Et3N·HCl was removed by filtration.  The Et2O was removed under vacuum 
and the residue dissolved in 1.7 mL DCM.  Cbz azide (0.77 mmol, 1.0 eq) was added 
dropwise at RT.  The reaction was then allowed to stir for 2 h.  The DCM was removed 
under vacuum and the crude mixture was subjected to flash chromatography (gradient 1:5 
hexanes/EtOAc to 1:2.5 hexanes/EtOAc).  The phosphorimidate decomposed upon 
standing and was thus used immediately upon isolation.
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To a solution of DCM (20 mL) was added the phosphorimidate (0.2 mmol, 1.0 eq) 
and 3 mol% PdCl2(CH3CN)2.  The reaction was stirred at room temperature with 
monitoring by TLC (1:1 hexanes/EtOAc) for 5-7h, at which time starting material was no 
longer present.  The DCM was then removed under vacuum and the crude mixture was 
immediately subjected to flash chromatography (1:5 hexanes/EtOAc to 1:2.5 
hexanes/EtOAc to 1:1 hexanes/EtOAc) to provide the product allenamide.  Note that 
prolonged exposure to palladium salts leads to decomposition and epimerization.
Benzyl diethoxyphosphoryl(propa-1,2-dienyl)carbamate (A2-2): Prepared via the 
general procedure  in 76% yield (57 mg) from the corresponding phosphorimidate (82% 
yield) as a colorless oil. 1H NMR: δ 1.27 (t, J = 6.6 Hz, 6H), 4.00-4.15 (m, 4H), 5.19 (dd, 
J = 3.5, 6.3 Hz, 2H), 5.22 (s, 2H), 6.33 (dd, J = 6.4, 13.3 Hz, 1H), 7.29-7.39 (m, 5H); 13C 
NMR: δ 15.93 (d, J = 8.6 Hz), 64.19 (d, J = 7.6 Hz), 68.6, 83.6, 95.6, 135.1, 153.4, (d, J 
= 9.5 Hz), 206.4 (d, J = 5.8 Hz); IR (film): 2984, 1731, 1455, 1441, 1383, 1283, 1026 cm-
1; HRMS (ESI) calcd for [C15H20NO5P+Na]+: 348.0977, found: 348.0972. 
Benzyl buta-1,2-dienyl(diethoxyphosphoryl)carbamate (A2-4):  Prepared via the 
general procedure in 68% yield (44 mg) from the corresponding phosphorimidate (71% 
yield) as a colorless oil.  1H NMR: δ 1.29 (t, J = 7.5 Hz, 6H), 1.72 (dd, J = 2.5, 7.2 Hz, 
3H), 4.08-4.22 (m, 4H), 5.25 (s, 2H), 5.57-5.60 (m, 1H), 6.22- 6.24 (m, 1H), 7.33-7.42 
(m, 5H); 13C NMR δ: 14.3 (d, J = 2.0 Hz), 16.0 (d, J = 3.4 Hz), 64.1 (d, J = 3.4 Hz), 64.1 
(d, J = 3.4), 68.5, 94.6 (d, J = 3.4 Hz), 94.9, 128.2, 128.4, 128.5, 135.3, 153.7 (d, J = 9.6 
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Hz), 202.1 (d, J = 5.4 Hz); IR (film): 2984, 1728, 1456, 1381, 1276, 1024 cm-1; HRMS 
(ESI) calcd for [C16H22NO5P+Na]+: 362.1133, found: 362.1126.
(S)-Benzyl buta-1,2-dien-1-yl(diethoxyphosphoryl)carbamate (A2-6): Prepared via 
the general procedure in 70% yield from the corresponding phosphorimidate (56% yield) 
as a colorless oil.  1H and 13C data identical to that outlined for compound 4 [α]D23= -53.7 
(c = 1, CH2Cl2) .  92% ee (Chiral HPLC Chiralcel OJ column, flow rate 1 mL/min, 0.4 % 
hexanes in IPA, detected at 240 nm. Rt = 16.63 (maj), 19.58 (min), see supplementary 
HPLC traces.
(R)-Benzyl buta-1,2-dien-1-yl(diethoxyphosphoryl)carbamate (A2-8): Prepared via 
the general procedure in 67% yield from the corresponding phosphorimidate (72% yield) 
as a colorless oil.  1H and 13C data identical to that outlined for compound 4.  92% ee 
(Chiral HPLC Chiralcel OJ column, flow rate 1 mL/min, 0.4 % hexanes in IPA, detected 
at 240 nm. Rt = 16.30 (min), 18.44 (maj), see supplementary HPLC traces.
Benzyl diethoxyphosphoryl(penta-1,2-dienyl)carbamate (A2-10): Prepared via the 
general procedure in 68% yield (54 mg) from the corresponding phosphorimidate (25% 
yield) as a pale yellow oil.  1H NMR: δ 1.01 (t, J = 7.0 Hz, 3H), 1.27 (t, J = 7.0 Hz, 6H), 
2.03-2.10 (m, 2H), 4.04-4.21 (m, 4H), 5.22 (s, 2H), 5.59-5.65 (m, 1H), 6.22-6.26 (m, 
2H), 7.30-7.41 ( m, 5H); 13C NMR: δ 12.9, 16.0 (d, J = 6.9 Hz), 22.2 (d, J = 1.5 Hz), 64.0 
(d, J = 6.1 Hz), 68.4, 95.5 (d, J = 2.3 Hz), 101.6, 128.1, 128.3, 128.4, 135.3, 153.7  (d, J 
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= 7.7 Hz),  201.0 (d, J = 4.6 Hz); IR (film): 2967, 1728, 1380, 1278 1024 cm-1; HRMS 
(ESI) calcd for [C17H24NO5P+Na]+: 376.1290, found: 376.1281.
Benzyl  diethoxyphosphoryl(octa-1,2-dien-1-yl)carbamate  (A2-12):  Prepared  via  the 
general procedure in 70% yield (55 mg) from the corresponding phosphorimidate (67% 
yield) as a pale yellow oil.  1H NMR: δ 0.86 (t, J = 7.2 Hz, 3H), 1.22-1.30 (m, 10H), 1.40 
(m, 2H), 2.04 (m, 2 H), 4.02-4.21 (m, 4H), 5.21 (s, 1H), 5.53-5.59 (m, 1H), 6.18-6.22 (m, 
1H), 7.30-7.40 (m, 5H); 13C NMR: δ 14.0, 16.0 (d, J = 8.8 Hz), 22.4, 28.4, 28.8 (d, J = 
1.3 Hz), 31.3, 64.1 (d, J = 7.3 Hz), 68.4, 95.0 (d, J = 3.4 Hz), 100.1, 128.1, 128.3, 128.5, 
135.3, 153.7 (d, J = 10.1 Hz), 201.3 (d, J = 5.8 Hz); IR (film): 2957, 1732, 1456, 1380, 
1277, 1026 cm-1; HRMS (ESI) calcd for [C20H24NO5P+Na]+: 418.1759, found: 418.1755.
(S)-Benzyl diethoxyphosphoryl(octa-1,2-dien-1-yl)carbamate (A2-14):  Prepared via 
the general procedure in 70% yield (44 mg) from the corresponding phosphorimidate 
(81% yield) as a pale yellow oil.  1H and 13C data identical to that outlined for compound 
A2-12. 
[α]D23= -50.9 (c = 1 CH2Cl2).  80% ee (Chiral HPLC Chiralcel OJ column, flow rate 1 
mL/min, 0.3% hexanes in IPA, detected at 254 nm. Rt = 10.97 (maj), 12.68 (min).  The 
yield increased with extended reaction times but epimerization was observed.  See 
supplementary HPLC traces.
Benzyl diethoxyphosphoryl(4-methylhepta-1,2-dienyl)carbamate (A2-16):  Prepared 
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via the general procedure, with the exception that the rearrangement took 12 h for 
depletion of starting material, in 65% yield (51 mg) from the corresponding 
phosphorimidate (77% yield) as a pale yellow oil.  The reported product is a mixture of 2 
diastereomers derived from the 2 diastereomers present as a 1:1 mixture in the starting 
alcohol.  1H NMR: δ 0.86 (t, J = 6.8 Hz, 3H), 1.00 (d, J = 6.8 Hz, 3H) 1.22-1.36 (m, 8H), 
2.19-2.28 (m, 1H), 4.05-4.21 (m, 4H), 5.22 (s, 1H), 5.48-5.55 (m, 1H), 6.22 (dt, J = 2.6, 
6.2 Hz, 1H), 7.30-7.41 (m, 5H); 13C NMR: δ 14.0, 14.1, 15.9, 16.0, 19.8, 19.9, 20.2, 33.5 
(d, J = 1.4 Hz), 33.7, 38.3, 38.9, 64.0 (d, J =  6.3 Hz), 64.0 (d, J = 4.8 Hz), 68.4, 95.5 (d, 
J = 3.3 Hz), 95.6 (d, J = 3.4 Hz) 105.7, 105.8, 128.1, 128.2, 128.4, 135.3, 153.7 (d, J = 
10.0 Hz), 200.4 (d, J = 4.6 Hz); IR (film): 2958, 1731, 1456, 1379, 1275, 1026 cm-1; 
HRMS (ESI) calcd for [C20H24NO5P+Na]+: 418.1759, found: 418.1749.  
Benzyl buta-2,3-dien-2-yl(diethoxyphosphoryl)carbamate (A2-18): Prepared as stated, 
with the exception that the rearrangement was carried out in toluene at 100 °C for 12h on 
a 0.6 mmol scale (0.23 g phosphorimidate), in 58% yield (125 mg) from the 
corresponding phosphorimidate (75% yield) as a pale yellow oil.  1H NMR: δ 1.28 (dt, J 
= 0.8, 7.0, 6H), 1.28 (t, J = 7.0 3H), 1.99 (dt, J = 1.2, 3.1 Hz 3H), 4.04-4.22 (m, 4H), 
5.00-5.04 (m, 2H), 5.22 (s, 2H), 7.32-7.40 (m, 5H); 13C NMR: δ 16.0 (d, J = 6.9 Hz), 
19.7, 64.0 (d, J = 5.4 Hz), 68.2, 80.0 (d, J = 2.3 Hz), 105.0, 127.9, 128.2, 128.5, 135.5, 
153.7 (d, J = 9.2 Hz), 208.4 (d, J = 4.7 Hz); IR (film): 2983, 1728, 1497, 1455, 1380, 
1271, 1024 cm-1;  
HRMS (ESI) calcd for [C16H22NO5P+Na]+: 362.1133, found: 362.1121.
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Benzyl diethoxyphosphoryl(penta-1,2-dien-3-yl)carbamate (A2-20):  Prepared via the 
general procedure, with the exception that the rearrangement was carried out in toluene at 
100°C, in 58% yield (32.5 mg) from the corresponding phosphorimidate (75% yield) as a 
colorless oil.  1H NMR: δ 0.99 (t, J = 7.6 Hz, 3H), 1.25 (dt, J = 0.8, 6.8 Hz, 6H),  2.18-
2.28 (m, 2H) 4.00-4.18 (m, 4H), 5.08-5.11 (m, 2H), 5.18 (s, 2H), 7.30-7.40 (m, 5H); 13C 
NMR:  δ  11.0, 16.0 (d, J= 8.8 Hz), 25.7, 64.0 (d, J= 7.3 Hz), 68.2, 82.1 (d, J= 2.4 Hz), 
111.0, 127.8, 128.2, 128.4, 135.5, 153.9 (d, J= 11.6 Hz), 207.7 (d, J= 4.9 Hz); IR (film): 
2977, 1727, 1456, 1380, 1278, 1025 cm-1; HRMS (ESI) calcd for [C17H24NO5P+Na]+: 
376.129, found: 376.1277.
Benzyl diethoxyphosphoryl(hexa-3,4-dien-3-yl)carbamate (A2-22): Prepared via the 
general procedure, with the exception that the rearrangement was carried out in toluene at 
100°C on a 0.1 mmol scale (41 mg phosphorimidate), in 60% yield (25 mg) from the 
corresponding phosphorimidate (48% yield) as a yellow oil. 1H NMR: δ 0.98 (t, J = 7.4 
Hz, 3H), 1.28 (dt, J = 0.8, 7.2 Hz, 6H), 1.69 (d, J = 5.4 Hz, 3H), 2.21-2.27 (m, 2H), 4.03-
4.21 (m, 4H), 5.37 (dd, J = 12.5, 19.5 Hz, 2H), 5.46-5.52 (m, 1H), 7.30-7.38 (m, 5H); 13C 
NMR: δ 11.1, 14.1 (d, J = 2.9 Hz), 16.0 (d, J = 7.6 Hz), 26.2, 63.8 (d, J = 3.8 Hz), 63.9 
(d, J = 3.9 Hz), 68.0, 93.4 (d, J = 2.9 Hz), 110.0, 127.8, 128.1, 128.4, 135.6, 154.0, 203.0 
(d, J = 4.9 Hz); IR (film): 2978, 1726, 1456, 1378, 1272, 1024 cm-1; HRMS (ESI) calcd 
for [C18H26NO5P+Na]+: 390.1446, found: 390.1444. 
Benzyl diethoxyphosphoryl(hexa-2,3-dien-2-yl)carbamate (A2-24):  Prepared via  the 
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general procedure, with the exception that the rearrangement was carried out in toluene at 
100°C, in 58% yield (42.5 mg) from the corresponding phosphorimidate (50% yield) as a 
yellow oil.   1H NMR: δ 0.99 (t, J = 7.6 Hz, 3H), 1.27 (t, J = 7.2 Hz, 6H), 1.97 (dd, J= 
1.2, 2.8 Hz, 3H), 2.03 (dq,  J= 2.4, 8.6 Hz, 2H), 4.04-4.19 (m, 4H), 5.20 (s, 2H), 5.40-
5.48 (m, 1H), 7.30-7.40 (m, 5H); 13C NMR: δ 13.1, 16.0 (d J = 9.1 Hz), 20.3, 22.1 (d, J = 
3.3 Hz), 63.5 (d,  J= 5.1 Hz), 68.1, 98.2 (d,  J= 2.4 Hz), 105.0 (d,  J  = 1.0 Hz), 128.0, 
128.2, 128.4, 135.5, 153.9 (d, J = 11.9 Hz), 202.7 (d, J = 5.3 Hz); IR (film): 2980, 1728, 
1456, 1380, 1277, 1026cm-1; HRMS (ESI) calcd for [C18H26NO5P+Na]+: 390.1446, found: 
390.1445.
(Z)-benzyl bicyclo[2.2.1]hept-5-en-2-ylidenemethyl(diethoxyphosphoryl)carbamate 
(A2-25)
Allenamide A2-2 (70 mg, 0.22 mmol) was combined with freshly cracked 
cyclopentadiene (0.18 mL, 2.2 mmol) in toluene (0.4 mL) under N2. The reaction was 
sealed and heated to 100º C for 8 hours, after which the toluene was removed under 
reduced pressure and the crude reaction mixture was purified by flash chromatography 
(25-50% ethyl acetate in hexanes) to yield 23 as a clear oil (63 mg, 0.16 mmol, 73%). 
Configuration determined by 1D NOESY. 1H NMR: δ 1.24 (dt, J = 0.4, 6.8 Hz, 3H), 1.25 
(dt, J = 0.8, 6.8 Hz, 3H), 1.41 (d, J = 8.4 Hz, 1H),  1.58 (d, J = 10 Hz,1H),  1.71*1.75 (m, 
1H), 2.16*2.20 (m, 1H), 2.92 (s, 1H), 3.27 (s, 1H),  4.00*4.16 (m, 4H), 5.12*5.17 (m, 
2H), 5.95 (d, J = 2.5 Hz, 1H), 5.99*6.00 (m, 1H), 6.12*6.13 (m, 1H), 7.26*7.32 (m, 5H); 
13C NMR: δ 16.03 (d, J = 2.3 Hz), 16.10 (d, J = 2.7), 31.93, 41.42, 48.36, 50.36, 
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64.02*64.13 (m), 68.08, 114.1, 127.9, 128.0, 128.2, 128.4, 133.3 (d, J = 1.9), 135.5, 
137.7, 146.8 (d, J = 4.67 Hz), 154.1 (d, J = 10 Hz), IR (film): 3000, 1731, 1455, 1441, 
1383, 1283, 1026 cm*1; HRMS (ESI) calcd for [C20H26NO5P+Na]+: 414.1446, found: 
414.1444. 
(E)-benzyl diethoxyphosphoryl(3-oxo-3-phenyl-2-((4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)methyl)prop-1-enyl)carbamate (A2-26)
To allenamide A2-2 (35 mg, 0.107 mmol) was added bis(pinacolato)diboron (31 mg, 
0.12mmol) and Bis(acetonitrile)dichloropalladium(II) (1.4 mg, 0.0055 mmol), and a stir 
bar. The flask was evacuated and purged with nitrogen 3 times, followed by the addition 
of Toluene (0.44 mL) and benzoyl chloride (distilled from Calcium Chloride, 15 μL, 0.13 
mmol). The reaction was heated to 80º C under nitrogen for 6 hrs after which the solvent 
was removed under reduced pressure and the crude reaction was purified by flash 
chromatography (25-50% ethyl acetate in hexanes) to give 24 as a clear oil (28 mg, 0.050 
mmol, 47%).  Configuration of major isomer determined by 1D NOESY. 1H NMR: δ 1.18 
(s, 9H), 1.24 (dt, J = 1, 6 Hz, 6H), 1.97 (s, 2H),  4.06*4.20 (m, 4H), 5.21 (s, 2H), 
6.51*6.52 (m, 1H), 6.58 (m, 1H, Z isomer), 7.30*7.39 (m, 7H), 7.44*7.48 (m, 2H), 
7.71*7.73 (m, 2H), 8.04*8.06 (m, 2H, Z isomer). 13C NMR: δ 13.48 (d, J = 6.7 Hz), 
16.77, 22.21, 62.08 (d, J = 6.23 Hz), 66.26, 80.86, 125.5, 125.7, 125.9, 126.0, 126.0, 
127.2, 127.6, 129.4, 131.8, 132.5, 135.5, 137.6 (d, J = 4.8 Hz), 150.3 (d, J = 8.2 Hz), 
194.8, IR (film): 2923, 1717, 1685, 1279, 1208, 1142, 1026 cm*1; HRMS (ESI) calcd for 
[C28H37BNO8P+Na]+: 580.2248, found: 580.2260.
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